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Abstract 
Sustained EGFR/Ras/MAPK signaling is associated with various cancers. Hence, blocking 
EGFR and its downstream effectors has become an established target in anti-cancer 
therapeutics. However, targeted agents face several challenges which limit their clinical use 
such as inter-patient variation, mutation, and resistance. Therefore, the identification of 
biomarkers that could predict the treatment outcome in cancer patients is crucial. Annexin A6 
(AnxA6) is a calcium-dependent membrane binding protein with potential tumor suppressor 
properties. It was shown to bind and promote the involvement of p120GAP and protein 
kinase Cα (PKCα), two negative regulators of the EGFR/Ras/MAPK pathway, in the signal 
termination of this cascade. Increasing evidence points at the involvement of scaffold 
proteins, like AnxA6, in the sensitivity of cancer cells towards anti-cancer drugs. In this 
study, we examined the influence of single and combinatorial treatments targeting the 
EGFR/Ras/MAPK signaling cascade on the oncogenic proliferation of A431 cells in the 
presence and absence of AnxA6. Using A431wt cells, which lack endogenous AnxA6, and 
A431-A6 cells, a well characterized cell line which stably overexpress AnxA6, we 
investigated clonogenic growth in the presence of the EGFR tyrosine kinase inhibitors (TKIs) 
erlotinib and gefitinib, the EGFR-targeted monoclonal antibody cetuximab, the MEK1/2 
inhibitor PD98059, and the PKCα inhibitors BIM-I and Gö 6976 via clonogenic and MTS 
assays. We found that treating the cells with TKIs, MEK1/2 or PKCα inhibitors was able to 
effectively reduce colony and cell growth more than the individual drugs, and this inhibition 
was more pronounced in AnxA6 overexpressing cells. Furthermore, combinatorial treatment 
of A431 cancer cells with TKIs together with MEK1/2 inhibitors was more effective in cells 
expressing AnxA6. The data presented here suggest AnxA6 as a possible biomarker that 
could predict treatment outcome in EGFR-related cancers.  
9 
 
Chapter 1: Introduction 
1.1 Overview 
Epidermal growth factor receptor (EGFR)/Ras/mitogen-activated protein kinase (MAPK) 
pathway is one of the targets that are under investigation for the treatment of cancer. Strong 
evidence points at the significant influence of mutations on the occurrence of tumors with 
high frequency of reported EGFR, Ras, and Raf mutations (1-10). In fact, the three isoforms 
of Ras (H-, K-, and N-Ras) were found mutated in different types of cancer and were shown 
to occupy 20-30 % of human cancers. These mutations lead to failure of Ras inactivation and 
a sustained cell proliferation (11-15). EGFR mutations were also reported and were 
associated with a more aggressive disease and a poorer prognosis (1-9). In addition, it was 
shown that EGFR overexpression could lead to a hyperactive wild type Ras with a 
subsequent cellular oncogenic transformation (16-19). Moreover, the heterodimerization of 
EGFR with other deregulated ErbB receptors and its transactivation by heterogeneous signals 
were also linked to cancer with increased cell growth, angiogenesis, and metastasis (1-9). 
Therefore, drugs targeting EGFR/Ras/MAPK pathway have developed into several potent 
anticancer medications (3, 9, 20).  
However, different regulatory factors in the EGFR pathway seem to modulate/potentiate drug 
efficiency in patients. This also includes several scaffold proteins that are involved in the 
regulation of EGFR signaling such as cortactin, caveolin, and annexin A6 (AnxA6). AnxA6 
is a calcium-dependent membrane binding protein that is suggested to have tumor suppressor 
properties owing to its inhibitory effect on the EGFR/Ras/MAPK pathway. Although AnxA6-
KO mice appear normal and do not develop spontaneous tumors (3, 21), several studies 
correlated the loss of AnxA6 with increased EGFR/Ras/MAPK activity and cell proliferation 
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(3, 16, 22, 23). For example, human A431 carcinoma cells, which overexpress EGFR and 
show elevated Ras/MAPK activity, lack endogenous AnxA6 (3, 16, 22, 23). However, upon 
ectopic expression of AnxA6, Ras/MAPK activity and cell growth were reduced in A431 
cells (3, 16, 22-25). Likewise, several estrogen receptor-negative breast cancer cell lines 
showed reduced AnxA6 levels that upon elevation via AnxA6 overexpression, EGFR/Ras 
was inhibited (3, 22). In addition, the transformation of prostate cancer and human melanoma 
from benign to malignant phenotypes showed AnxA6 downregulation correlating with 
deregulated EGFR and hyperactive Ras (3, 16, 26, 27). Also the metastatic development of 
B16F10 mouse melanoma showed AnxA6 downregulation (3, 16). This suggests a strong 
relationship between reduced AnxA6 levels and elevated Ras activity in EGFR 
overexpressing cancer cells leading to a significant influence on EGFR/Ras/MAPK pathway, 
a cascade that is highly regulated to control cell proliferation and differentiation. 
1.2 The EGFR/Ras/MAPK pathway 
EGFR or ErbB-1 is a member of the ErbB family that has three other members, HER2 (ErbB-
2), HER3 (ErbB-3), and HER4 (ErbB-4). It is a transmembrane receptor with an extracellular 
region, which binds ligands such as EGF and EGF-like molecules, and an intracellular 
domain with a tyrosine kinase activity (17, 28). Its enzymatic activity is kept inactive as long 
as the receptor is in the monomeric state, but following ligand binding, EGFR dimerization is 
triggered leading to receptor activation. Consequently, the active tyrosine kinase in one 
receptor phosphorylates the tyrosine residues present in the other receptor in an 
autophosphorylation process (2, 8, 29), leading to the formation of phosphotyrosine-
containing motifs which act as docking sites for adaptor proteins (Figure 1A). Growth factor 
receptor-binding protein-2 (Grb2) is an adaptor protein which associates with these motifs 
and then binds simultaneously to the son of sevenless (SOS) (30). SOS is a guanine 
nucleotide exchange factor which activates the membrane bound Ras by exchanging the Ras-
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bound guanosine diphosphate (GDP) with guanosine triphosphate (GTP) (31). Ras activation 
leads to the recruitment and activation of the serine/threonine-protein kinase Raf. Activated 
Raf then phosphorylates and activates MEK1/2 which in turn phosphorylates and activates 
ERK1/2 (MAPK) (19). Finally, activated ERK1/2 phosphorylates nuclear proteins and 
modulates the activity of several transcription factors regulating gene expression to induce 
cell growth and differentiation.  
Overactivity of the EGFR pathway is associated with oncogenesis (16, 22, 32, 33). Hence, 
EGFR downregulation has been recognized as an important step in the cell to prevent 
oncogenic events.  
1.3 EGFR/Ras/MAPK signal termination  
The EGFR/Ras/MAPK pathway is a highly regulated process that involves the cooperation of 
multiple proteins in order to initiate signal termination and prevent sustained cell proliferation 
and differentiation (1, 3-8). Following receptor activation, the signal is terminated through 
the internalization of EGFR via endocytosis. Then, the endocytic vesicles traffic through late 
endosomes (LE) and/or multivesicular bodies (MVB) to lysosomes for degradation and signal 
termination (Figure 1A). Although the Ras/MAPK pathway proteins can remain associated 
with EGFR along this route, the majority of Ras is transported back to the plasma membrane 
via the recycling endosomes (1, 3, 6, 7, 16, 22).  
It was revealed that EGFR internalization occurs through clathrin coated pits (CCP) and to a 
lower extent via caveolae/lipid rafts depending on EGFR concentration. At low EGFR 
concentration, EGFR internalization occurs through CCP leading to either its lysosomal 
degradation or recycling (3, 34, 35). However, at high EGFR concentration both CCP and 
caveolae/lipid rafts are involved in EGFR internalization, with the caveolae/lipid raft pathway 
leading only to EGFR degradation not recycling (1, 3, 6, 7, 35-37). This two way mechanism 
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can help the cell to deal with any physiological concentrations of EGF (~ 1-100 ng/ml) and to 
prevent its overstimulation (1, 3, 5-7, 35-37).  
The inhibition of the EGFR/Ras/MAPK cascade involves multiple proteins such as protein 
kinase Cα (PKCα), p120GAP, and calmodulin. PKCα is a classical isoform of the 
serine/threonine PKC family that is activated by the second messengers, calcium and 
diacylglycerol (DAG), at the plasma membrane, endosomes, Golgi or mitochondria (38, 39). 
Binding of phospholipase Cγ (PLCγ) to activated EGFR leads to the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) into DAG and inositol-1,4,5-triphosphate 
(IP3). IP3 binds IP3 receptors causing the release of the intracellular calcium stores in the 
endoplasmic reticulum, hence the intracellular calcium level increases (3, 5). DAG binds to 
the C1 domain of PKC and elevates the affinity of PKC to phosphatidylserine (PS) in 
membranes with subsequent conformational changes to allow substrate binding, while 
calcium association with the C2 domain of PKC leads to increased and stabilized membrane 
binding (38, 40-44). Then, PKCα phosphorylates EGFR at threonine 654 leading to the 
inhibition of its tyrosine kinase activity, internalization, and lysosomal degradation. AnxA6 
was also found to bind PKCα in a calcium-dependent manner and to potentiate both the 
transport of PKCα to the membrane and its ability to bind and inhibit EGFR (45-47). Finally, 
the inactive EGFR is targeted to the recycling endosomes which is responsible for 
transporting the EGFR back to the plasma membrane in a highly regulated process involving 
the actin cytoskeleton (19) (Figure 1B).  
GTPase activating proteins (GAPs) such as p120GAP are other negative regulators of EGFR 
and Ras. Although a role for p120GAP in EGFR inhibition has been described, it is not well 
understood. In contrast, the role of GAPs in Ras inactivation is well documented. When 
GAPs translocate to the plasma membrane and bind to Ras, Ras GTPases are inactivated and 
switch from the active (Ras-GTP) to the inactive (Ras-GDP) (13, 14, 48). In EGFR 
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overexpressing cancer cells, p120GAP was reported to bind to AnxA6. This binding 
stabilized H-Ras/p120GAP assembly and led to H-Ras inactivation (19, 22, 49-51) (Figure 
1C). 
 
 
 
Figure 1. (A) EGFR signal termination. (1) When EGF binds EGFR in cells with low AnxA6 levels, EGFR 
dimerization and a subsequent tyrosine kinase activation is followed by signal termination via (2,3) endocytosis 
and (4) lysosomal degradation. (B) The role of AnxA6 and PKCα in EGFR signal termination. (1) EGF binds to 
EGFR leading to receptor dimerization and activation. (2) AnxA6 and PKCα interact in the cytosol which leads 
to PKCα membrane binding potentiation. (3) PKCα phosphorylates EGFR at threonine 654 which inhibits its 
tyrosine kinase activation and reduces its internalization. (4) AnxA6 and PKCα remain attached to EGFR in 
early endosomes (EE). (5) Finally, AnxA6 and PKCα dissociate from EGFR which is sent to the plasma 
membrane for recycling for another round of signaling. (C) The role of AnxA6 and p120GAP in EGFR signal 
termination. (1,2) AnxA6 and p120GAP interact in the cytosol of resting cells with AnxA6 potentiating the 
targeting of p120GAP to the plasma membrane when EGF binds EGFR and calcium levels increase. (3) A 
complex of several proteins is formed which includes EGFR, p120GAP, AnxA6, and H-Ras which leads to the 
inactivation of H-Ras and signal termination. (4) The complex is internalized. (5) AnxA6/p120GAP complex 
dissociate into the cytosol, H-Ras recycles to the plasma membrane, and EGFR is either targeted to the recycling 
endosomes or to late endosomes/ multivesicular bodies (LE/MVB). Taken from (19). 
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Calmodulin (CaM) is another example of a protein that can inhibit EGFR/Ras pathway at 
multiple levels. CaM is a small protein found abundantly in most eukaryotic cells. It can 
activate calmodulin-dependent protein kinase II (CaMK-II), which phosphorylates EGFR 
leading to the inhibition of its tyrosine kinase activity and a subsequent decrease of Ras 
signaling (3, 14, 52). Out of the three Ras isoforms, CaM can release K-Ras from the plasma 
membrane inhibiting its activation (3, 53, 54). In addition, CaM can directly bind to EGFR in 
a calcium-dependent interaction inhibiting its tyrosine kinase activity at the plasma 
membrane (55), disrupting PKC binding at threonine 654 (56, 57), and preventing EGFR 
signaling (3, 58). Moreover, CaM regulates the endocytosis and trafficking of EGFR through 
endosomes (3, 59-61).  
In addition to these negative regulators of the EGFR/Ras pathway, AnxA6 also has a 
significant role in the downregulation and signal termination of the EGFR/Ras/MAPK 
pathway and, as outlined in more details below, it is considered as a promising target to 
develop a novel treatment for cancer (3, 10). 
1.4 Annexin A6 
Annexins are a group of structurally related proteins that have the ability to bind negatively 
charged phospholipids in a calcium-dependent manner. They are found in different species 
ranging from protists to humans in most cell types and tissues with the exception of annexin 
A8 which is only found in lung, skin, liver and kidney (3, 62-65). They are divided into five 
groups (A-E) with the 12 proteins found in human and vertebrates occupying group A (19).  
Annexins consist of two domains; the first one is the variable N-terminal tail, while the other 
is the conserved C-terminal annexin core that contains calcium and phospholipid binding 
sites. All annexins have one core with four repeats of a 70 amino acids sequence except 
AnxA6, which has two cores with eight disk-like repeats connected by a flexible linker 
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(Figure 2) (66). Hence, AnxA6 may attach to one or two membranes owing to the flexible 
orientation of these two cores relative to each other.  
It was proposed that the duplication and fusion of the genes encoding for annexin A5 and 
annexin A10 may be the reason for this unique structure of AnxA6 among all other annexins 
(19, 67-70). Chromosome 5q32-q34 harbors the AnxA6 gene which is ~60.000 bp long with 
26 exons (Figure 2).  
 
Figure 2. The gene and protein structure of AnxA6. The exon-intron structure of the AnxA6 gene and the 
eight annexin repeats of AnxA6 protein are illustrated; exons and annexin repeats are numbered and represented 
as boxes. The amino acid positions of each repeat are indicated. The lengths of regions in kilobases (kb) within 
the AnxA6 gene are indicated. The asterisk indicates the position of the alternatively spliced exon 21 (black 
box). The first two exons code for the N-terminus, while exons 3-13 and 16-26 code for repeats 1-4 and 5-8, 
respectively. The amino acid sequence of a potential F-actin binding site (Pos. 274–281), the p120GAP binding 
domain within the linker region (Pos. 325–363), and the larger splice variant (Pos. 524–529) are indicated. 
Phosphorylation sites at serine 13, tyrosine 30 and threonine 356 are given. Taken from (66).  
 
AnxA6 was shown to bind PS, phosphatidylinositol, phosphatidic acid (65), with some 
affinity for phosphatidylethanolamine, and arachidonic acid (19, 71). It was found at the 
plasma membrane, early endosomes (EE), LE, and recycling endosomes (3, 16, 65, 72-85) 
with some studies indicating its presence in mitochondria (86), lipid droplets (87) and the 
secretory pathway (44, 65, 80, 88-90). 
In Chinese hamster ovary cells (CHO), 70-80% of AnxA6 proteins were found attached to 
membranes in a calcium-dependent manner, while the rest was found linked to endosomal 
membranes in a calcium-independent manner with a potential influence of cholesterol. It was 
demonstrated that cholesterol is a potential modulator of AnxA6 membrane binding affinity 
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as well as its intracellular localization. In one study cholesterol was depleted by methyl-β-
cyclodextrin which reduced the calcium-independent membrane binding affinity of AnxA6 to 
early and late endosomes. On the other hand, the use of Low-density lipoprotein (LDL) or 
U18666A to load cells with cholesterol in LE stimulated AnxA6 binding to late endosomal 
membranes (72, 85). In addition to cholesterol, pH was found to affect the membrane binding 
affinity of AnxA6. Conformational changes of AnxA6 were observed in acidic pH which 
increased its hydrophobicity, membrane binding affinity and enhanced its binding to 
monolayers containing cholesterol (19, 91-93). 
AnxA6 has two mRNA isoforms, the full-length AnxA6-1 and the shorter isoform AnxA6-2 
which lacks 524-VAAEIL-529 from the seventh repeat (Figure 2). AnxA6-1 is found more 
abundant in normal tissues and cells, while AnxA6-2 is highly expressed in some transformed 
cell lines (94). AnxA6-2 has lower hydrophobicity, more calcium affinity and lower negative 
surface charge (95), but AnxA6-1 is the isoform that was found to have an inhibitory effect 
on EGF-dependent calcium influx in A431 cells (19, 96). However, despite these findings, 
the overall roles of the two AnxA6 mRNA isoforms have remained elusive. 
1.5 The role of annexin A6 in the EGFR/Ras/MAPK pathway 
AnxA6 influences the EGFR/Ras/MAPK pathway through its multifunctional properties 
relevant for signal transduction, endocytosis and lysosomal degradation, actin dynamics, 
caveolae/lipid raft formation and cholesterol homeostasis (45, 65, 73-80, 97, 98). 
The tumor suppressor effect of AnxA6 is suggested to be a consequence of its potential 
influence on EGFR signaling. AnxA6 potentiates EGFR signal termination via several 
protein-protein interactions involving multiple Ras regulators/effectors such as PKCα, Raf-1, 
and p120GAP (29, 99, 100). AnxA6 was found to be a scaffold for PKCα via an interaction 
possibly involving the C2 domain of PKCα and the threonine 356 residue in the AnxA6 
linker region (90, 101). Thus, AnxA6 plays a significant role in the association of PKCα to 
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membranes by acting as a docking site as well as potentiating its membrane binding, in order 
to promote PKCα-mediated inhibition of the EGFR signaling (Figure 1B) (3, 19, 29, 44, 102, 
103). AnxA6 was also found to be a scaffold for p120GAP, most likely through the 
association of the AnxA6 linker region with the C2 domain of p120GAP (100, 104), which is 
important for the inactivation of Ras, and it was proposed that AnxA6 is part of and stabilizes 
the HRas-GTP/p120GAP complex (23) to ensure Ras inactivation. Here, AnxA6 may act as 
the calcium sensor of p120GAP which lacks the aspartate residues necessary for the calcium-
dependent membrane targeting (Figure 1C) (19, 23, 105, 106). In summary, AnxA6 
potentiates the involvement of p120GAP and PKCα in H-Ras and EGFR signal termination. 
AnxA6 was also found to play a significant role in the internalization and lysosomal 
degradation of endocytic vesicles. It was reported that LDL receptor-mediated endocytosis 
occurs after a sequence of interactions that starts with the association of AnxA6 with spectrin 
and a subsequent calcium and cysteine-dependent protease (calpain-1) recruitment. Then, 
calpain-1 cleaves the actin-spectrin cytoskeleton to make remodeling of the spectrin 
cytoskeleton leading to the release of the endocytic vesicle into the cytosol with AnxA6 
attached to it (3, 72-74). Similarly, AnxA6 translocates to LE upon elevation of LDL or 
cholesterol levels in them (72, 85). This may induce spectrin reorganization, leading to the 
release of the budding vesicles from LE for degradation in the lysosomes (19, 74, 84). 
Likewise, AnxA6 was found associated with EGFR targeted for lysosomal degradation (44). 
Altogether, this suggests the crucial role of AnxA6 in endocytosis and lysosomal degradation. 
Several cellular functions of AnxA6 are facilitated via its highly dynamic interaction with the 
actin cytoskeleton which may not only impact on EGFR endocytosis and degradation (3, 107-
110), but also on EGFR recycling (59, 60). It was demonstrated that upon calcium elevation 
AnxA6 binds F-actin (111, 112), and both co-localize at membrane ruffles (112, 113) and 
circular-dorsal ruffles leading to a membrane-cytoskeleton interaction as well as cortical 
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cytoskeleton stabilization (114). AnxA6 was also found to bind spectrin which in turn 
influences the F-actin bundling activity in a PS- and calcium-dependent manner (115). In 
addition, annexin-actin interaction was demonstrated to be involved in the regulation of store-
operated calcium entry (SOCE) as reduced SOCE was observed following the stabilization of 
the cortical cytoskeleton (19, 114, 116-118). 
Moreover, AnxA6 regulates EGFR mobility and distribution at the cell surface through 
controlling caveolae/lipid rafts formation directly via its interaction with phospholipids, actin, 
and signaling proteins or indirectly through the regulation of the intracellular distribution of 
cholesterol. The cholesterol-containing particles known as LDL are internalized from the cell 
surface via receptor-mediated endocytosis. In this process, AnxA6 interacts with the 
endocytic machinery including dynamin and AP1 leading to LDL endocytosis. Following 
internalization, the endocytic vesicle fuses with EE, then later targeted to lysosomes (66, 
119). Generally little amounts of cholesterol are found in LE and lysosomes in normal cells. 
However, increased AnxA6 levels were shown to sequester cholesterol in LE and prevent its 
transport to the plasma membrane or the Golgi apparatus possibly via the cholesterol 
transporter Niemann Pick Type C1 (NPC1). Cholesterol depletion in the Golgi prevents the 
binding of cholesterol-sensitive cytosolic phospholipase A2 (cPLA2) to the Golgi, which is 
required to stimulate the transport of caveolin from the Golgi to the plasma membrane. 
Consequently, caveolin-1 is sequestered in Golgi, and caveolae formation is inhibited (3, 66, 
75, 76) (Figure 3). It was reported that cells with increased AnxA6 showed a significant 
reduction of condensed membrane domains and suggested the ability of AnxA6 to promote 
changes in membrane architecture (19). These microdomain forming abilities of AnxA6 are 
likely to affect EGFR signaling and trafficking. 
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Figure 3. The role of AnxA6 in late endosomal cholesterol transport and caveolae/lipid raft formation. 
AnxA6 interacts with the endocytic machinery (dynamin, AP1) and induces the remodeling of the actin-spectrin 
cytoskeleton leading to low-density lipoprotein receptor (LDLR)-mediated endocytosis to early endosomes (EE) 
and lysosomal targeting of LDL. (1,2) In cells with high AnxA6 levels, AnxA6 translocates to multivesicular 
bodies/late endosomes (MVB/LE) upon LDL or cholesterol elevation. (3) AnxA6 interferes with Niemann Pick 
Type C1 (NPC1) protein to inhibit the transport of cholesterol to the Golgi apparatus. (4,5) Cholesterol 
depletion in the Golgi inhibits the binding of cytosolic phospholipase A2 (cPLA2) to the Golgi leading to the 
prevention of caveolin transport from the Golgi to the plasma membrane. (6) Caveolae formation is reduced as a 
result of decreased amounts of caveolin-1 and cholesterol at the plasma membrane. Taken from (66).  
 
1.6 EGFR/Ras/MAPK pathway inhibitors 
The crucial role that the EGFR/Ras/MAPK signaling cascade plays in cancer and other 
diseases has led to an intense research focusing on developing inhibitors of the pathway. 
Small molecule inhibitors blocking Raf or MEK1/2 as well as tyrosine kinase inhibitors and 
monoclonal antibodies targeting EGFR are examples of these inhibitors. 
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1.6.1 MEK1/2 inhibitors 
MEK1 and MEK2 are closely related dual-specificity kinases that are activated by Raf 
kinases. Following their activation, they phosphorylate ERK1 and ERK2 kinases at 
serine/threonine and tyrosine residues leading to their activation (120). MEK and ERK were 
reported to be highly activated in cancer which attracted the interest of researchers to develop 
MEK inhibitor molecules in order to block the oncogenic signaling in a targeted approach 
(120, 121). PD98059 is one of the early compounds that were synthesized to block MEK1/2. 
It is a small molecule that performs its action via binding to the inactive form of MEK1/2 at a 
site other than the active site. Subsequently, the phosphorylation and activation of MEK1/2 
are inhibited in a process that does not involve competing adenosine triphosphate (ATP) at 
the catalytic site, which may explain the high selectivity of the compound (120, 122). 
PD98059 is an important experimental tool for exploring the MEK-ERK pathway in studies 
targeting the role of ERK signaling in cancer (20, 120, 123). 
1.6.2 EGFR inhibitors 
Several approaches have been developed to inhibit the EGFR in order to treat cancer. The 
most clinically advanced approaches are monoclonal antibodies (mAbs) and tyrosine kinase 
inhibitors (TKIs), which perform their actions by two different mechanisms. Monoclonal 
antibodies bind to the extracellular ligand-binding domain of EGFR followed by 
internalization of the EGFR-mAb complex and inhibition of the signaling cascade. In 
contrast, tyrosine kinase inhibitors interact with the intracellular TK domain of the receptor 
by competing with ATP for the binding site. Thus, the enzymatic activity of the receptor is 
inhibited as well as its autophosphorylation leading to the inhibition of the EGFR signaling 
pathway (124, 125). These two mechanisms of action have been utilized to develop 
anticancer medications. For example, cetuximab (Erbitux
®
) is a chimeric monoclonal 
antibody that was approved for the treatment of metastatic colorectal and head and neck 
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cancers, as well as Panitumumab (Vectibix
®
), which is an approved fully humanized 
monoclonal antibody for metastatic colorectal cancer treatment. On the other hand, gefitinib 
(Iressa
®
) and erlotinib (Tarceva
®
) are two examples of approved tyrosine kinase inhibitors 
that are used to treat non-small-cell lung carcinoma (NSCLC) (126). 
Although these medications are very successful in the treatment of cancer patients, their 
clinical use is still limited. Resistance to EGFR inhibitors, expression levels of EGFR 
regulatory factors and the not well characterized tumor microenvironment appear to influence 
drug efficiency. 
1.6.3 Resistance to EGFR inhibitors 
Cancer cells often have genetic mutations that lead to a sustained cell growth and an intrinsic 
resistance to some anticancer therapies. They can also develop an acquired resistance to 
EGFR inhibitors after a prolonged exposure to these medications (127, 128). Multiple 
mechanisms of action were reported to explain the reason behind this observed resistance; 
mutations are the most common ones. For example, KRAS gene mutations represent 35-40% 
of resistant cases and were demonstrated to be responsible for the resistance of lung 
adenocarcinoma against gefitinib and erlotinib (129, 130). The mutation of the catalytic 
subunit α of phosphatidylinositol 3-kinase (PI3KCA) and the inactivation of its negative 
regulator phosphatase and tensin homolog deleted on chromosome 10 (PTEN) were also 
found abundantly and were shown to cause resistance to mAbs targeting EGFR in colorectal 
cancer (131, 132). In addition, the expression of the mutated variant EGFRvIII produced cells 
with ligand-independent EGFR phosphorylation that showed resistance to gefitinib in 
glioblastoma multiform (133). Another example is the EGFR mutation in position 790 as a 
result of the substitution of threonine by methionine (T790M), which causes resistance as a 
consequence of the steric hindrance exhibited by the bulky methionine preventing TKIs from 
binding EGFR (126, 134, 135).   
22 
 
In addition, other mechanisms have been suggested. For example, NSCLC were reported to 
develop acquired resistance following the transactivation of HER2 and HER3 (136) and not 
to respond to cetuximab following hepatocyte growth factor receptor activation (126, 137). 
Head and neck squamous cell carcinomas (HNSCC) with cyclin D1 gene amplification 
and/or overexpression showed resistance to gefitinib (138, 139). Altered angiogenesis and the 
production of proangiogenic growth factors such as vascular endothelial growth factor 
(VEGF) and basic fibroblast growth factor (bFGF) could also be responsible for resistance to 
EGFR inhibitors (139). The activation of alternative growth factor receptor systems, such as 
insulin-like growth factor-I receptor (IGF1R), has also been associated with EGFR TKI 
resistance (126, 140).  
Furthermore, up- or down-regulation of factors that regulate EGFR signaling and trafficking 
may also contribute (141). This includes scaffold proteins, which organize and stabilize the 
assembly and disassembly of EGFR signaling complexes at the plasma membrane and during 
endocytosis. Elevated expression of these scaffold proteins can lead to the increased 
recruitment of EGFR adaptors or effectors, thereby affecting signaling output. For example, 
cortactin overexpression led to a sustained EGFR signaling and an increased cell 
proliferation in HNSCC cells, in addition to a decreased sensitivity towards gefitinib (141, 
142). Other scaffold proteins, such as caveolin and kinase suppressor of Ras (KSR), have 
also been reported to affect TKI sensitivity (143-148). This indicates that expression levels of 
scaffold proteins may serve as prognostic markers that predict the response towards EGFR-
targeted therapies. However, markers with potential role in EGFR-related cancers still need 
to be identified. This would enable the medical team to provide patients with the proper 
treatment and to avoid medications, and consequently their undesired side effects.  
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1.7 PKC enzymes as targets for cancer treatment 
PKC plays a critical role in cancer that led research to target this group of enzymes for anti-
cancer drug development (41). PKC is a family of enzymes that phosphorylate serine and 
threonine residues of many proteins. They are encoded by nine genes and consist of 12 
isozymes which were divided into three groups depending on their structures and regulation. 
The classical or conventional PKCs consist of PKCα, PKCβI, PKCβII, and PKCγ isozymes 
which all require calcium and DAG for activation and bind to negatively charged membrane 
phospholipids, specially PS. The second group is known as the novel PKCs which consist of 
PKCε, PKCδ, PKCθ, and PKCη isozymes; these PKC isozymes do not need calcium for 
activation but require DAG and PS. The atypical PKCs are the last group with PKCζ and 
PKCλ/ι as its members that do not require either calcium or DAG for activation but can be 
activated by PS (44, 149, 150).  
Many PKC isozymes had been reported to associate with several physiological processes that 
are important for cancer. PKCα was found to be involved in cell proliferation, differentiation, 
apoptosis, cell cycle regulation, and cell adhesion (151); while PKCβ was reported to have a 
critical role in vasculogenesis (152). The level of some PKC isozymes was noted to increase 
in some cancers. For example, PKCθ is overexpressed in gastrointestinal stromal cancer 
(153), PKCη in NSCLC (154), and PKCε in colon, stomach, thyroid, lung, and breast cancers 
(155). Evidence also indicates the relation between the increased level of PKCη and cancer 
aggressiveness and proliferation (156), and correlates PKCδ activation to increased 
angiogenesis in prostate cancer (41, 157). As described above (section 1.3), out of the PKC 
family, PKCα is an important negative regulator of the EGFR and the Ras/MAPK pathway. 
Hence, the PKC family was considered as a possible anti-cancer therapeutic target, promoting 
research for the development of isozyme-specific PKC inhibitors. 
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BIM-I (also known as GF109203X or Gö 6850) is a potent PKC inhibitor. It is a 
bisindolylmaleimide derivative that inhibits α, β and γ isoforms. It performs its action through 
targeting the ATP-binding site of the kinase catalytic domain of PKC (158-160). Another 
example of a more selective PKC inhibitor is the indolocarbazole derivative Gö 6976 which 
is a selective inhibitor of both α and β1 isozymes. Similar to BIM-I, it functions as a 
competitive inhibitor at the ATP binding site of PKC (161). Specific PKC inhibitors are 
important experimental compounds in studies aiming at exploring PKC as a possible anti-
cancer therapeutic target.  
1.8 Phospholipase A2 
Besides PKC, members of the PLA2 family have also been associated with EGFR activation 
in cancer. Hence, PLA2 was suggested as a possible target for cancer therapy (162, 163). 
Phospholipase A2 (PLA2) is a set of esterase enzymes that catalyze the hydrolysis of 
glycerophospholipids at the sn-2 ester bond to yield a lysophopholipid and a fatty acid (162, 
163). They are divided into five groups; secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2), 
Ca
+2
-independent PLA2 (iPLA2), platelet-activating factor hydrolases (PAF-AH), and 
lysosomal PLA2 (162, 164-166). sPLA2 enzymes use histidine residues for the hydrolysis 
process and require Ca
+2 
for their activity, while cPLA2 and iPLA2 do not utilize histidine, but 
serine for the ester bond cleavage. cPLA2 does not require Ca
+2
 for activation, rather Ca
+2
 is 
needed for their translocation to membranes. In contrast, iPLA2 does not require Ca
+2
 for 
either activity or translocation (163, 165). Also, PAF-AH and lysosomal PLA2 utilize serine 
residues in the hydrolysis process but on two different substrates; PAF-AH hydrolyzes the 
acetyl groups of PAF, while lysosomal PLA2 catalyzes the hydrolysis of ceramide at its C-1 
position (162, 166). The different isozymes of PLA2 were found to correlate with cancer. 
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1.9 Phospholipase A2 and cancer 
PLA2 enzymes were found to have a wide range of functions in different physiological 
processes. Evidence supports their role in cell growth (163, 167-171), cell signaling (163, 
172-175), cell death (163, 164, 176, 177), inflammation (163, 172, 178, 179), and 
maintenance of membrane phospholipids (163, 180-182). It was reported that PLA2 levels 
increase in several human cancers such as breast, colorectal, lung and prostate cancers (163, 
183-191).  
Several mechanisms were suggested to explain the role of PLA2 in cancer formation. It was 
reported that PLA2 cleaves glycerophospholipids into arachidonic acid and 
lysophospholipids; both of them are further metabolized into other molecules that were found 
to induce cell growth (163, 192-194). One important molecule is lysophosphatidic acid 
(LPA), which is released following the metabolism of lysophospholipid. It activates G-
protein coupled receptors leading to the elevation of secondary messengers, cytosolic calcium 
and cAMP, and the subsequent activation of certain enzymes that can contribute to cancer 
formation such as PKC and Ras/MAPK (163, 194). It was also reported that iPLA2 leads to 
the transactivation of EGFR in prostate and ovarian cancers (162, 195, 196) and that it 
regulates MAPK activity (162, 197-199).  
Given that PLA2 enzymes are considered as possible targets for anti-cancer agents and that 
AnxA6 inhibits caveolae formation via cPLA2 (3, 66, 75, 76), PLA2 inhibitors were 
considered in the studies presented here. Methyl arachidonyl fluorophosphonate (MAFP) is 
an example of a PLA2 inhibitor which irreversibly inhibits cPLA2, and to some extent iPLA2. 
It is a phosphonate analogue of arachidonic acid that prevents the catalytic function of cPLA2 
via its direct interaction with the serine residues at the active site of cPLA2 (200, 201). 
Grewal and coworkers had previously shown the potency of MAFP to mimic AnxA6 activity 
and inhibit the export of caveolin from the Golgi (75). 
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1.10 Combinatorial targeted therapy 
The increased knowledge of cancer pathogenesis revealed its complex multigenic nature. 
Usually cancer therapy depends on killing rapidly dividing cells; an approach that has several 
limitations such as the narrow therapeutic index, acquired resistance, and overlapping 
toxicities (202-204). This justified the replacement of single-targeted drugs by combinatorial 
therapies (202-204). Combinatorial targeted treatments can be described as either vertical, 
which targets the same oncogenic signal transduction pathway at several steps, or horizontal, 
which targets several parallel pathways (202). Such approaches can overcome resistance and 
lead to increased efficacy and decreased toxicity.  
An example of a combinatorial therapy is the mAb trastuzumab combined with the 
antimitotic chemotherapeutic agent docetaxel for the treatment of patients with human 
epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The addition of 
trastuzumab to the treatment, as compared to chemotherapy alone, increased the overall 
survival in these patients (205, 206). However, HER2 dimerization with other members of the 
HER family such as HER3 and EGFR led to trastuzumab resistance and a subsequent 
continued signaling transduction (207). This resistance was successfully targeted in the 
CLEOPATRA study via the triple therapy of trastuzumab, pertuzumab, and docetaxel; a 
combination that is now FDA approved. Pertuzumab is a humanized mAb which targets a 
HER2 epitope other than that of trastuzumab (202, 208-210). 
Other successful approved combinations include the use of lapatinib, an EGFR and HER2 
tyrosine kinase inhibitor, in combination with the antimetabolite chemotherapeutic agent 
capecitabine in the treatment of HER2-overexpressing metastatic breast cancer (202, 211, 
212). Similarly, the monoclonal antibody cetuximab combined with the topoisomerase I 
inhibitor cytotoxic agent irinotecan are used for the treatment of patients with metastatic 
colorectal cancer (202, 213, 214). 
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1.11 Hypothesis and Aims 
Over the years, several small molecules and monoclonal antibodies targeting EGFR-related 
pathways have been developed. In spite of the success of many TKIs and antibodies as anti-
cancer EGFR agents, their clinical use is still very limited not only due to patient variability, 
but also the development of drug resistance, phenomena that are not well understood (125, 
126, 130, 133-135). As outlined above (Section 1.10), one approach to overcome these issues 
is the replacement of single-targeted drug treatments by combinatorial therapies aiming to 
inhibit additional targets in the EGFR/Ras/MAPK pathway (202-204). This includes the 
combination of EGFR-TKIs and anti-EGFR antibodies (215, 216). In addition, the use of 
anti-EGFR drugs together with (vertical) Raf-1 or Mek1/2 inhibitors, that act downstream of 
EGFR, appears very promising (for review see (217-219)). Furthermore, the combination of 
EGFR and PKC inhibitors has also been considered, as PKC inhibition promotes not only 
apoptosis through other regulatory circuits, but also downregulates EGFR/Ras/MAPK 
signalling (220, 221).  
Despite these promising approaches, there is still little knowledge how to identify patients 
that will respond well to single or combinatorial anti-cancer treatments aiming to block 
oncogenic EGFR. Hence, there is a great demand for biomarkers to predict the treatment 
outcomes and the potential development of drug resistance. As outlined above, scaffold 
proteins are essential for the formation and disassembly of signalling complexes. Thus, high 
and low expression levels of a particular scaffold protein can promote or inhibit the 
formation of multifactorial protein complexes. In the previous sections, the role of AnxA6 as 
a scaffold protein to recruit negative regulators of the EGFR/Ras/MAPK pathway has been 
described (Sections 1.4 and 1.5). High levels of AnxA6 increase the recruitment of PKCα 
and p120GAP to the plasma membrane, thereby increasing EGFR/PKCα and Ras/p120GAP 
complex formation, leading to inhibition of EGFR and Ras, respectively (22, 23, 29, 44, 100, 
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102, 104, 105). Based on these observations, it is tempting to speculate that reduced numbers 
of active EGFR- and Ras/MAPK containing protein complexes in cells with high AnxA6 
levels would lessen the amount of drug required to inhibit the remaining pool of active EGFR 
and Ras/MAPK in every cancer cell.  
Hence, we hypothesize that high AnxA6 level will improve the efficacy of single or 
combinatorial treatments targeting EGFR-related cancer cell growth. To address the 
hypothesis, we will focus on the following aims: 
 
Aim 1: To compare the efficacy of EGFR-TKIs (erlotinib, gefitinib, AG1478) in EGFR 
overexpressing cancer cells with high and low AnxA6 levels. 
Aim 2: To compare the efficacy of monoclonal anti-EGFR antibodies (cetuximab) in EGFR 
overexpressing cancer cells with high and low AnxA6 levels. 
Aim 3: To compare the efficacy of EGFR-TKIs (erlotinib, gefitinib) in combination with 
anti-EGFR antibodies in EGFR overexpressing cancer cells with high and low AnxA6 levels. 
Aim 4: To compare the efficacy of EGFR-TKIs (erlotinib, gefitinib) in combination with 
MEK1/2 or PKC inhibitors in EGFR overexpressing cancer cells with high and low AnxA6 
levels. 
To address these aims, we will determine clonogenic growth and measure cell proliferation 
(MTS) ± drugs in EGFR-overexpressing A431 cells that lack AnxA6 (A431wt) or 
overexpress AnxA6 (A431-A6). The identification of AnxA6 upregulation improving drug 
sensitivity could develop the determination of Anx6 expression as a prognostic tool to predict 
drug efficacy in patients with EGFR-related cancers. 
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1.11.1 Cell model and study design 
To address the aims listed above, human epidermoid A431 carcinoma cells were utilized. 
This cell line, with approximately 1-3 x 10
6
 EGFR per cell, represents the classical model to 
study oncogenic EGFR activity due to EGFR overexpression (222). A431 wild type cells 
(A431wt) lack endogenous AnxA6. On the other hand, Grewal and coworkers established a 
stably transfected A431 cell line that overexpresses AnxA6. This cell line is well 
characterized (22, 72, 114), with AnxA6 expression levels comparable to endogenous AnxA6 
levels found in many cells and tissues (3, 66, 223, 224). Moreover, A431-A6 cells display 
reduced EGFR and Ras/MAPK activity compared to A431wt cells (29). Hence, the 
comparison of growth inhibition upon exposure to EGFR/Ras/MAPK inhibitors in A431wt 
versus A431-A6 cells is ideal to identify if elevated AnxA6 levels provide an opportunity for 
improved drug efficacy. We employed the colony formation assay in our investigations 
which is well documented to reflect the oncogenic potential of a cancer cell (Figure 4). It is a 
commonly used test to investigate the effectiveness of anti-cancer therapeutics. 
 
Figure 4. Scheme illustrating study design. The colony formation assay was adopted to determine if elevated 
AnxA6 levels increase drug efficacy in A431 cells. A431wt (lack endogenous AnxA6) and A431-A6 (stably 
express AnxA6) cells were treated with TKIs (erlotinib or gefitinib), mAb (cetuximab), MEK1/2 inhibitor 
(PD98059) and PKCα inhibitors (BIM-I, Gö6976) alone (monotherapies) or in combination (combinatorial 
treatment) as indicated. 
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1.11.2 Drug selection 
The focus of this study was to determine if the presence of AnxA6 improves anticancer drug 
performance. Hence, rather than analyzing novel EGFR-TKIs or anti-EGFR antibodies, that 
are being developed currently, we reasoned that commercially available anti-EGFR drugs 
would provide the opportunity to deliver proof-of-principle. Hence, drugs were selected 
based on their mechanisms of action in relation to the EGFR/Ras/MAPK pathway and 
AnxA6 (Figure 5). TKIs and mAbs are the two major classes of EGFR inhibitors, which 
function by two different mechanisms to block EGFR signaling (124, 125). We selected three 
FDA approved drugs that are commercially available in our investigations, erlotinib and 
gefitinib as examples of TKIs, and cetuximab as an example of mAb (126). In addition, in 
one set of experiments, to further validate erlotinib- and gefitinib-based data, we tested 
AG1478, which is considered more potent than erlotinib and gefitinib (225-228). 
MEK1/2 acts downstream of EGFR and is critical to propagate the growth-promoting signal 
from EGFR. As combinatorial drug treatments of EGFR and MAPK inhibitors have provided 
potential to improve treatment efficacy (229-231), we included the combination of EGFR-
TKIs with MEK1/2 inhibitors. MEK1/2 is highly activated in EGFR-related cancers (120, 
121) and can be blocked effectively with PD98059, a small molecule that is highly selective 
for MEK1/2 within the MAPK protein family (120, 122). It is considered a useful 
experimental tool in exploring the MEK-ERK pathway in cancer studies (20, 120, 123).  
PKCα was also targeted in this study. Blocking PKC activity has long been considered an 
option to reduce oncogenic cell behavior. As described in the introduction (section 1.3), 
AnxA6 facilitates the membrane recruitment and association of PKCα with EGFR, leading to 
EGFR Threonine 654 phosphorylation and consequently EGFR inactivation. As PKCα 
knockdown restores EGFR activity in A431-A6 cells (29), we reasoned that blocking PKCα 
activity via small molecules might interfere with the ability of AnxA6 to negatively regulate 
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EGFR signaling (45-47). As outlined in the results and discussion, we chose Gö6976 and 
BIM-I in our investigations, which are commonly used in the field and represent two potent 
PKC inhibitors (158-161).  
In addition, some experiments were performed with cPLA2 inhibitors (MAFP). These studies 
are based on the ability of AnxA6 to inhibit cPLA2-dependent membrane trafficking events 
(3, 19, 66, 75, 76) that might interfere with the cell surface expression of EGFR. 
As the combinatorial treatment of EGFR inhibitors with anti-EGFR antibodies as well as 
MAPK and PKC inhibitors has provided promising results previously (215, 229-234), we 
decided to test the efficacy of all of the above drugs alone and in combination. To reduce the 
complexity, the number of control samples required, and to reduce the risk of undesired drug-
drug interactions, we limited the project to analyzing drugs alone or in pairs.  
 
Figure 5. EGFR/Ras/MAPK pathway highlighting the different inhibitors used in this study. The 
association of EGF to EGFR induces receptor dimerization and TK activation, followed by autophosphorylation 
of the receptor. Grb2 is an adaptor protein which binds phosphorylated EGFR and other TK residues. 
Consequently, SOS binds Grb2 and activates Ras by exchanging the inactive Ras-GDP with active Ras-GTP. 
This leads to the recruitment and activation of the serine/threonine-protein kinase Raf. Activated Raf then 
phosphorylates and activates MEK1/2, which in turn phosphorylates and activates ERK1/2. Then, activated 
ERK phosphorylates nuclear proteins and modulates the activity of several transcription factors regulating gene 
expression to induce cell growth and differentiation. Annexin A6 is a scaffold protein for p120GAP and PKCα, 
both are negative regulators of the EGFR signaling pathway. p120GAP inactivates Ras, while PKCα 
phosphorylates EGFR at threonine 654 leading to the inhibition of its TK activity. The selection of inhibitors 
used in this study was based on their mechanisms of action. Cetuximab is a monoclonal antibody which binds 
the extracellular ligand-binging domain of EGFR, thereby blocking EGF ligand binding. In contrast, erlotinib 
and gefitinib represent TKIs which compete with ATP for the intracellular binding site in the EGFR tyrosine 
kinase domain. Finally, Gö 6976 and BIM-I are two potent PKC inhibitors, while PD98059 is a selective 
MEK1/2 inhibitor. 
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Chapter 2: Materials and Methods 
2.1 Study drugs 
To investigate the impact of inhibiting EGFR, MAPK, PKCα and cPLA2 (alone or in 
combination) on cancer cell growth, commercially available EGFR-TKIs (erlotinib, gefitinib, 
AG1478), MAPK (MEK1/2 inhibitor PD98059), PKCα (BIM-I, Gö6976) and cPLA2 
(MAFP) inhibitors, as well as a clinically used monoclonal EGFR antibody available through 
collaborators (cetuximab) were analyzed. Erlotinib, gefitinib, MAFP, and BIM-I were 
purchased from Cayman Chemical Company (Ann Arbor, Michigan, USA). Gö6976 and 
AG1478 were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia), while PD98059 
was from Sigma-Aldrich (St. Louis, Missouri, USA). Cetuximab was kindly provided by Dr. 
Fiona Simpson (The University of Queensland Diamantina Institute, Brisbane, Queensland, 
Australia). 
2.2 Cell culture 
The human epidermoid carcinoma A431 cell line was chosen as this cell line represents the 
classical model to investigate oncogenic EGFR activity due to EGFR overexpression (29, 
222). This cell line expresses approximately 1-3 x 10
6
 EGFR per cell, and has been utilized 
in numerous studies to investigate the efficacy and mode of action of EGFR-TKIs as well as 
monoclonal antibodies targeting EGFR. A431wt cells lack endogenous AnxA6, and A431-
A6 stably express AnxA6 at levels that are commonly observed in many cells and tissues (3, 
22, 66, 72, 114, 223, 224), making the two cell lines ideal to compare anticancer drug 
efficacy in the absence or presence of AnxA6.  
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2.2.1 Culture media 
Cells were cultured in Dulbecco's Modified Eagle's medium (DMEM, Gibco, USA) 
formulated with low glucose (1 g/L), sodium pyruvate (110 mg/L), and GlutaMAX
™
-I 
(500ml DMEM (1X) + GlutaMAX
™
-I). The media were supplemented with 10% fetal bovine 
serum (FBS, Gibco, USA) and 1% penicillin/streptomycin (Gibco, USA). 
2.2.2 Culture of A431wt and A431-A6 cells 
A431wt cells were purchased from the American Type Culture Collection (ATCC; 
Manassas, VA, USA), while the stable A431-A6 cell line was generated in the Grewal 
laboratory (23).  
Cells grown in tissue cultures lose their characteristic features when cultured for an extensive 
long period. This is associated with changes in cell morphology and growth behavior, which 
can affect the experimental outcome. To ensure reproducibility of results, cells growing no 
longer than 15 passages were used. This required the freezing of cells very early in this 
project to ensure a reliable source of cells throughout the 1-year project. The protocol to 
preserve A431 cells was as follows: Preservation in liquid nitrogen was adapted for long term 
storage of the cells using freezing media with DMEM (1X) + GlutaMAX
™
-I, 20% FBS, and 
10% DMSO. Frozen cells were thawed as follows: The cells were quickly thawed in a 37°C 
water bath, added to 6ml culture media, and centrifuged at 1400 rpm for 5 minutes. The 
supernatant was removed by suction, and 5ml of Dulbecco's phosphate-buffered saline 
(DPBS calcium, magnesium, and Phenol Red free, Gibco, USA) was added in which the cells 
were resuspended, and then centrifuged for 5 minutes at 1400 rpm. The supernatant was 
removed, and cells were resuspended in 6ml media and transferred to a T25 cell culture flask 
(Corning Incorporated Life Sciences, USA) which was then placed in a humidified incubator 
at 37°C and 5% CO2. When 60-70% confluency was reached, the cells were transferred to a 
T75 cell culture flask and passaged twice a week thereafter.  
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2.2.3 Passaging of A431wt and A431-A6 cells 
To avoid cell overgrowth and consequently apoptosis, passaging of the cell line ensures cell 
viability under standard culture conditions. Cancer cell lines such as A431 replicate 
approximately every 22-24 h, and when cultured in a 75 cm
2
 flask, they have to be passaged 
every 3-5 days to avoid overgrowth. In this technique, the culture medium was removed by 
suction using a Pasteur pipette, followed by washing cells with 2ml DPBS in order to remove 
dead cells debris and the remaining growth medium which contains FBS that can inhibit 
trypsin. Then, 2ml of the proteolytic enzyme trypsin (1X) (0.5% Trypsin-EDTA (10X); 
Gibco, USA) was added to detach the cells by disrupting the cell-substratum and cell-cell 
interactions. Cells were incubated with trypsin for 8 minutes in a humidified incubator at 
37°C and 5% CO2. The detachment was evaluated microscopically, using a Nikon Eclipse 
TS100 microscope, and enhanced by strongly tapping the flask to ensure the removal of all 
the cells from the surface. Then, 8ml of the culture media was added to deactivate trypsin. 
Finally, 1ml of cells was added to 9ml of fresh media to obtain a 1:10 split ratio. Cells were 
passaged twice per week and kept in a humidified incubator at 37°C and 5% CO2. 
2.3 Colony formation assay 
The growth inhibitory effect of drugs was evaluated using the colony formation assay (also 
known as the clonogenic assay). It is a commonly used assay to investigate the effect of anti-
cancer agents on the proliferative ability of transformed cell lines (235). It depends on the 
capacity of a single cell to retain its reproductive ability and to grow into a colony (236). 
Here, the test was used to compare the growth inhibitory effect of anticancer drugs targeting 
the EGFR/Ras/MAPK pathway in the presence or absence of AnxA6 in A431 cells. 
Therefore, A431wt and A431-A6 cells were passaged by trypsinization, counted using a 
haemocytometer, and plated in a six-well culture plates at a density of 7000 cells per well to 
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a total volume of 2ml culture medium. The plates were incubated overnight in a humidified 
incubator at 37°C and 5% CO2. 
On the following day, drugs were added at the appropriate concentrations to the cells. DMSO 
(less than 0.1%) was used as the negative control in all of the experiments except when 
cetuximab was tested for which only the culture medium was the control. Cells were 
incubated for further four to five days, depending on the growth rate, with and without drugs 
in a humidified incubator at 37°C and 5% CO2. 
Then, the cells were washed twice with DPBS, fixed with Diff Quik Fixative, and stained 
with Diff Quik stain (Lab Aids Pty Ltd, North Narrabeen, NSW 2101, Australia). Finally, 
cells were rinsed twice with deionized water and left for air dry. Photos for each well were 
taken by the camera of the cell phone Samsung Galaxy S6 Edge plus (16MP/ F1.9) to 
illustrate the density of colony formation in the wells. Ten images per well were randomly 
taken using the P.A.L.M. DuoFlex Combi System (Carl Zeiss) via 5X magnification; these 
ten images occupy an area of 3.34% of the total area of one well. The number of colonies in 
the images were counted and plotted against drug concentrations. The percentage of 
inhibition was calculated according to the equation (% inhibition= [(total number of colonies 
in the control well- total number of colonies in the sample well)/ total number of colonies in 
the control well] x 100). Each experiment was independently repeated three times unless 
otherwise indicated. 
 
2.4 Cell proliferation assay (MTS assay) 
To validate data sets obtained from clonogenic assays (see Section 2.3) on A431wt and 
A431-A6 cell growth ± anticancer drugs, cell proliferation was additionally determined using 
the MTS assay. This assay determines the metabolic activity of cells and is a convenient 
methodology to assess cell proliferation and the cytotoxic potential of compounds through 
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colorimetric determination of metabolic activity. The concept of the assay is the bioreduction 
of the tetrazolium compound by the dehydrogenase enzymes of the metabolically active cells 
into formazan. Formazan is an aqueous compound that is soluble in the tissue culture 
medium. Its absorbance can be measured directly from the 96-well plate at 490 nm, and it is 
directly proportional to the number of metabolically active (living) cells.  
In our experiments CellTiter 96
®
Aqueous Non-Radioactive Cell Proliferation Assay Kit 
(Progema) was used which is composed of an electron coupling reagent (phenazine 
methosulfate; PMS) and a tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS). The preparation 
of the reagents included thawing both the 100ml PMS and the 5ml MTS, combining both 
solutions together, and then storing the final solution in 5ml tubes at -20°C for later use. 
The following protocol was adapted in our experiments. A431wt and A431-A6 cells were 
seeded in 96-well plates at a density of 4000 and/or 8000 cells per well in growth medium 
(90µl cell suspension/well) and left overnight in a humidified incubator at 37°C and 5% CO2. 
On the following day, drugs were added to the wells at the appropriate concentrations. Then, 
the plates were put back in the humidified incubator at 37°C and 5% CO2 for additional three 
days without changing the medium. Quadruple repeats were made for each drug treatment. 
Then, 20µl of the prepared MTS solution was added to each well, and the plates were 
incubated for 30-60 minutes in a humidified incubator at 37°C and 5% CO2. The absorbance 
was detected at 490 nm using Bio-Rad Model 680 microplate reader. Mean absorbance, 
percentage of viability, and percentage of growth inhibition for each drug dose were 
calculated. Then, percentage of viability or growth inhibition was plotted versus drug 
concentrations.  
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 Percentage of viability = [(mean absorbance from sample well – mean absorbance 
from medium (blank)/ (mean absorbance from solvent treated cells (control) – mean 
absorbance from medium (blank)] x 100 
 Percentage of growth inhibition = 100 – cell survival 
2.5 Statistical analysis 
Statistical analysis is critical when aiming at determining the significance of experimental 
data. Therefore, in order to obtain the statistical significance that AnxA6 expression impacts 
on drug performance, each experiment, unless stated otherwise in the figure legend, was 
performed at least 3 times. The results were expressed as the mean ± SEM except the results 
of representative experiments which were expressed as mean ± SD. The data was analyzed 
using GraphPad Prism version 6.07 software. The statistical analysis of all data was done by 
student’s unpaired t-test, in which we compared the results obtained from A431-A6 cells 
with that of A431wt control unless otherwise indicated. The P value < 0.05 was considered 
statistically significant (***P < 0.001; **P < 0.01; *P < 0.05).   
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Chapter 3: Results 
3.1 Increased anti-cancer potency of erlotinib in A431-A6 cells  
AnxA6 overexpression reduces the growth of A431 cells via its role in the downregulation of 
the EGFR/Ras/MAPK pathway (22, 23, 29, 99). We wanted to explore if this effect of 
AnxA6 could lead to increased potency of TKIs in A431 cells. Therefore, the inhibitory 
effect of erlotinib on the oncogenic growth of A431-A6 cells, which are well characterized 
and stably overexpress AnxA6 (22, 72, 114), and A431wt cells was compared by employing 
clonogenic assays. To completely abrogate EGFR signaling, EGFR TKIs are generally used 
at a concentration of 10µM in cell culture studies (234, 237). A431wt and A431-A6 cells 
were plated at low density and incubated with different erlotinib concentrations (1µM, 10µM, 
25µM) for five days to allow colony formation. Then, the cells were washed twice with 
DPBS, fixed and stained. Colonies of twenty or more cells were counted and plotted against 
erlotinib concentrations (Figure 6). The results revealed that the number of colonies 
decreased by 14.8% in A431-A6 control compared to A431wt control, which confirm the 
previous findings of our laboratory (22). The dose of 1µM erlotinib decreased the number of 
colonies in A431wt cells by 39.1% from 227 ± 37.7 to 138.3 ± 19.3, while in A431-A6 cells 
it was significantly decreased by 61.5% to 87.3 ± 24.4 (P =0.036), which illustrates the 
potentiating effect of AnxA6 on cell growth inhibition with a small dose of erlotinib. The 
dose of 10µM erlotinib significantly decreased the number of colonies by 97.5% (5.7 ± 1.8) 
in A431wt cells (P = 0.004), and by 99.6% (1 ± 1) in A431-A6 cells (P = 0.004). Lastly, the 
dose of 25µM caused 99.4% significant inhibition in A431wt colony formation (P = 0.004), 
and 100% inhibition in A431-A6 cells (P = 0.004) (Figure 7). The experiment was repeated 
three times with A431-A6 cells showing less colony formation than A431wt cells, and A431-
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A6 cells being more sensitive to erlotinib treatment than A431wt cells, suggesting that 
AnxA6 has an inhibitory effect on cell growth that is augmented by erlotinib treatment.               
3.2 MTS assay identifies increased growth inhibition in AnxA6 
expressing cells treated with erlotinib 
Erlotinib effectively inhibited A431 colony formation upon AnxA6 overexpression (Figure 6 
and 7). Previously Grewal and coworkers showed the increased potency of TKIs in the 
presence of AnxA6 using MTS assays (unpublished). To confirm these findings, A431wt and 
A431-A6 cells were seeded at a density of 4000 cells per well and incubated with different 
erlotinib concentrations (0.5µM, 1µM, 5µM, 10µM, and 50µM) for three days. Quadruple 
repeats were made for each treatment. Then, MTS reagent was added and the plates were 
incubated for 30 minutes. The absorbance was detected at 490 nm, and the percentage of 
viability was calculated and plotted against erlotinib concentrations. The results showed 
reduced viability of A431wt cells (93.8%, 83.7%, 59%, 44.9%, 37.7%) with increased 
amounts of erlotinib (0.5µM, 1µM, 5µM, 10µM, 50µM), respectively. Similarly, reduced 
viability of A431-A6 cells was observed (73.4%, 53.8%, 53.3%, 37.6%, 30.6%) with the 
above mentioned drug treatments, respectively (Figure 8). In support of the results observed 
in the clonogenic assays (Figure 6 and 7), the MTS data showed that A431-A6 cells are more 
sensitive to erlotinib treatment than A431wt cells, supporting our hypothesis that elevated 
AnxA6 expression can potentiate the growth inhibitory effect of erlotinib. 
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Figure 6. Clonogenic assay of A431wt and A431-A6 cells treated with 0-25µM erlotinib. (A) A431wt and 
A431-A6 cells were plated in six-well culture plates at a density of 7000 cells per well and treated with 1µM, 
10µM, and 25µM erlotinib for five days as indicated. Then cells were fixed and stained. One photo/well was 
taken to document the density of colony formation in the wells. (B) 10 images/well were randomly taken using 
the P.A.L.M. DuoFlex Combi System (Carl Zeiss). The arrows indicate colonies composed of 20 cells or more, 
while arrowheads point at colonies of less than 20 cells (see enlarged section). (C) Colonies of 20 cells or more 
were counted in 10 images/condition and plotted against erlotinib concentrations. The error bars represent the 
SD. Statistical analysis was performed using student’s unpaired t-test and based on the analysis of 10 
images/well that were randomly taken of the same experiment. * represent a significant decrease of colony 
formation compared to A431wt control; *** P < 0.001. 
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Figure 7. AnxA6 overexpression potentiates erlotinib-mediated growth inhibition in A431 cells. A431wt 
and A431-A6 cells were incubated with 1µM, 10µM, and 25µM erlotinib for five days. Colonies of 20 cells or 
more were counted. Data represents the mean ± SEM of three independent experiments. (A) The number of 
colonies of A431wt and A431-A6 were plotted against erlotinib concentrations. (B) The number of colonies of 
A431wt and A431-A6 were normalized to A431wt control and A431-A6 control, respectively, and plotted 
against erlotinib concentrations. (C) The number of colonies of A431wt and A431-A6 were normalized to 
A431wt control and plotted against erlotinib concentrations. Statistical analysis was performed using student’s 
unpaired t-test where * represents a significant decrease of colony formation compared to A431wt control; * P < 
0.05; ** P < 0.01 
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Figure 8. MTS assay showing the effect of erlotinib on A431wt and A431-A6 cell growth. A431wt and 
A431-A6 cells were seeded at a density of 4000 cells per well, and incubated with 0.5µM, 1µM, 5µM, 10µM, 
and 50µM erlotinib for three days. Quadruple repeats were made for each treatment. Then, MTS reagent was 
added and the plates were incubated for 30 minutes. The absorbance was detected at 490 nm, and the percentage 
of growth inhibition was calculated and plotted against erlotinib concentrations. The error bars represent the SD 
(n = 1). 
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3.3 AnxA6 overexpression potentiates the growth inhibition 
mediated by gefitinib 
To extend our findings of the increased sensitivity of A431-A6 cells towards erlotinib (Figure 
6 and 8), we next compared colony formation in A431wt and A431-A6 cells after gefitinib 
treatment. A431wt and A431-A6 cells were plated as described above (section  3.1) and 
incubated with different gefitinib concentrations (1µM, 10µM, 25µM) for five days to allow 
colony formation. Then, the cells were washed twice with DPBS, fixed and stained. Colonies 
of twenty or more cells were counted and plotted against gefitinib concentrations (Figure 9). 
In agreement with published data and the results shown in Figure 6 and Figure 8, the number 
of colonies in A431wt control was 254.7 ± 55.3 compared to 205.7 ± 30 in A431-A6 control 
which represents 19% less colony formation. The number of colonies in A431wt cells treated 
with 1µM, 10µM, and 25µM gefitinib was 164 ± 16.7, 35.3 ± 8.4, and 1.3 ± 0.9, which 
represents 35.7%, 86.1%, and 99.5% reduction of colony formation, respectively, that was 
found to be statistically significant for 10µM and 25µM gefitinib (P<0.05). On the other 
hand, the number of colonies in A431-A6 cells treated with 1µM, 10µM, and 25µM gefitinib 
was 125 ± 27, 19.7 ± 11.5, and 0.7 ± 0.7, respectively. These results revealed 51% reduction 
of colony formation in A431-A6 cells treated with 1µM gefitinib, and 92.3 % and 99.7% 
reduction of colony formation in A431-A6 cells treated with 10µM and 25µM gefitinib, 
respectively (P<0.05). Similar to the data obtained with erlotinib (Figure 6-8), an enhanced 
inhibition of growth after 1µM gefitinib treatment of A431-A6 cells compared to A431wt 
cells was observed, while an almost similar inhibition with 10µM and 25µM of the drug was 
apparent (Figure 10). The experiment was repeated three times which showed less colony 
formation in A431-A6 cells compared to A431wt cells and an increased potency of the drug 
at low concentrations in A431-A6 cells. 
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Figure 9. Clonogenic assay of A431wt and A431-A6 cells treated with 0-25µM gefitinib. (A) A431wt and 
A431-A6 cells were plated in six-well culture plates at a density of 7000 cells per well and treated with 1µM, 
10µM, and 25µM gefitinib for five days as indicated. Then cells were fixed and stained. One photo/well was 
taken to document the density of colony formation in the wells. (B) 10 images/well were randomly taken using 
the P.A.L.M. DuoFlex Combi System (Carl Zeiss). The arrows indicate colonies composed of 20 cells or more, 
while arrowheads point at colonies of less than 20 cells. (C) Colonies of 20 cells or more were counted in 10 
images/condition and plotted against gefitinib concentrations. The error bars represent the SD. Statistical 
analysis was performed using student’s unpaired t-test and based on the analysis of 10 images/well that were 
randomly taken of the same experiment. * represent a significant decrease of colony formation compared to 
A431wt control; *** P < 0.001. 
44 
 
C o n tro l 1  1 0  2 5
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
3 5 0
G e fitin ib  (µ M )
N
u
m
b
e
r
 o
f 
c
o
lo
n
ie
s
A 4 3 1 w t
A 4 3 1 -A 6
*
*
*
*
C o n tro l 1  1 0  2 5
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
G e fitin ib  (µ M )
N
u
m
b
e
r
 o
f 
c
o
lo
n
ie
s
 n
o
r
m
a
li
z
e
d
to
 c
o
r
r
e
s
p
o
n
d
in
g
 c
o
n
tr
o
l 
(%
)
A 4 3 1 w t
A 4 3 1 -A 6
*
*
*
*
C o n tro l 1  1 0  2 5
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
G e fitin ib  (µ M )
N
u
m
b
e
r
 o
f 
c
o
lo
n
ie
s
n
o
r
m
a
li
z
e
d
 t
o
 w
t 
c
o
n
tr
o
l 
(%
)
A 4 3 1 w t
A 4 3 1 -A 6
*
*
*
*
(A ) ( B ) (C )
 
Figure 10. AnxA6 overexpression potentiates gefitinib-mediated growth inhibition in A431 cells. A431wt 
and A431-A6 cells were incubated with 1µM, 10µM, and 25µM gefitinib for five days. Colonies of 20 cells or 
more were counted. Data represents the mean ± SEM of three independent experiments. (A) The number of 
colonies of A431wt and A431-A6 were plotted against gefitinib concentrations. (B) The number of colonies of 
A431wt and A431-A6 were normalized to A431wt control and A431-A6 control, respectively, and plotted 
against gefitinib concentrations. (C) The number of colonies of A431wt and A431-A6 were normalized to 
A431wt control and plotted against gefitinib concentrations. Statistical analysis was performed using student’s 
unpaired t-test where * represents a significant decrease of colony formation compared to A431wt control; * P < 
0.05. 
3.4 Gefitinib treatment effectively inhibits cell growth of AnxA6 
expressing cells 
Colony formation was effectively inhibited in A431-A6 cells treated with gefitinib (Figure 9 
and 10). Using MTS, Grewal and coworkers were recently able to show the increased 
potency of TKIs in AnxA6 overexpressing cells (unpublished). To confirm these findings, 
A431wt and A431-A6 cells were seeded at a density of 4000 cells per well and incubated 
with 10µM and 50µM gefitinib concentrations for three days. Quadruple repeats were made 
for each treatment. Then, MTS reagent was added and the plates were incubated for 30-60 
minutes. The absorbance was detected at 490 nm, and the percentage of growth inhibition 
was calculated and plotted against gefitinib concentrations. The results showed that the 
percentage of growth inhibition was 32.8% in A431wt cells compared to 63.8% in A431-A6 
cells after the treatment with 10µM gefitinib. When the drug dose was increased to 50µM, 
the percentage of growth inhibition became 81.5% in A431wt cells and 105.3% in A431-A6 
cells (Figure 11). The experiment was repeated three times, and the data shows that A431-A6 
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cells were more sensitive to gefitinib treatment than A431wt cells, suggesting that elevated 
AnxA6 levels potentiate the efficacy of TKIs. 
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Figure 11. MTS assay showing the effect of gefitinib on the growth of A431wt and A431-A6 cells. A431wt 
and A431-A6 cells were seeded at a density of 4000 cells per well and incubated with 10µM and 50µM gefitinib 
for three days. Quadruple repeats were made for each treatment. Then, MTS reagent was added and the plates 
were incubated for 30-60 minutes. The absorbance was detected at 490 nm, and the percentage of growth 
inhibition was calculated and plotted against gefitinib concentrations. Data represents the mean ± SEM of three 
independent experiments. 
 
3.5 AG1478 potently inhibits A431 cell growth 
To further validate our findings from MTS and clonogenic assays in which we used erlotinib 
or gefitinib (Figure 6 and 11), we next analyzed the inhibitory effect of another potent small 
molecule TKI inhibitor of EGFR, AG1478, on the oncogenic growth of A431 cells by 
employing the MTS assay. A431wt and A431-A6 cells were plated in 96 well plates at a 
density of 8000 cells per well, and incubated with 12.5µM and 15µM AG1478 for three days. 
Quadruple repeats were made for each treatment. Then, MTS reagent was added and the 
plates were incubated for 30 minutes. The absorbance was detected at 490 nm, and the 
percentage of growth inhibition was calculated and plotted against AG1478 concentrations. 
The results showed that the percentage of growth inhibition was 62.2% in A431wt cells 
compared to 84.2% in A431-A6 cells with 12.5µM AG1478 treatment. When the drug dose 
was increased to 15µM, the percentage of growth inhibition became 91.3% in A431wt cells 
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and 101.1% in A431-A6 cells (Figure 12). Compared to the results obtained with gefitinib 
(Figure 11), AG1478 required much lower dose to cause 100% growth inhibition in A431-A6 
cells, indicating a higher potency of AG1478 over gefitinib. In addition, the experiment 
further supports a model of A431-A6 cells being more sensitive to EGFR TKIs treatment 
than A431wt cells. 
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Figure 12. MTS assay showing the effect of AG1478 on A431wt and A431-A6 cell growth. A431wt and 
A431-A6 cells were seeded at a density of 8000 cells per well, and incubated with 12.5µM and 15µM AG1478 
for three days. Quadruple repeats were made for each treatment. Then, MTS reagent was added and the plates 
were incubated for 30 minutes. The absorbance was detected at 490 nm, and the percentage of growth inhibition 
was calculated and plotted against AG1478 concentrations. The error bars represent the SD (n = 1). 
 
3.6 Cetuximab reduces colony formation in A431-A6 cells 
As discussed previously, EGFR inhibitors include TKIs and mAbs, which interfere with 
EGFR signaling via two different mechanisms. TKIs are small molecules that compete with 
ATP for the intracellular TK domain of the receptor; while mAbs such as cetuximab bind to 
the extracellular ligand binding domain followed by internalization of the EGFR-mAb 
complex (124, 125). Given that AnxA6 reduces the growth of EGFR overexpressing cells, we 
next wanted to explore if this could lead to increased potency of mAbs targeting EGFR. 
Therefore, the inhibitory effect of cetuximab on the oncogenic growth of A431 cells was 
studied by employing the clonogenic assay. A431wt and A431-A6 cells were incubated with 
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different cetuximab concentrations (50µg/ml and 100µg/ml) for four days to allow colony 
formation. Then, cells were washed twice with DPBS, fixed and stained. In these set of 
experiments, to avoid overlooking the growth-inhibitory effects of AnxA6 occurring at later 
stages of cell growth and/or proliferation, colonies of thirty, forty and fifty cells or more were 
counted and plotted against cetuximab concentrations (Figure 13). Taking into consideration 
colonies of fifty cells or more, A431-A6 control showed 36.8% less colony formation than 
A431wt control. Upon 50µg/ml cetuximab treatment, colony formation was inhibited by 
7.9% (70 ± 4.1) in A431wt cells compared to 59.2% (31 ± 2.1) in A431-A6 cells, and with 
100µg/ml cetuximab the inhibition was -11.8% (85 ± 4.9) in A431wt cells compared to 
56.6% (33 ± 4.8) in A431-A6 cells. Similar trends were observed when we quantified the 
counts from colonies with 30, 40 cells or more (Figure 13). Surprisingly, the inhibition of 
colony formation was most prominent with 50µg/ml cetuximab treatment which may indicate 
the saturation of the receptor with the mAbs under these conditions (Figure 13C). These 
findings need to be validated and will require more investigation in the future. However, the 
preliminary results shown here suggest that A431-A6 cells are more sensitive than A431wt 
cells to cetuximab, further implicating AnxA6 as a marker in predicting improved outcomes 
for anti-EGFR cancer therapies.                                                           
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Figure 13. Clonogenic assay of A431wt and A431-A6 cells treated with 0-100µg/ml cetuximab. (A) A431wt 
and A431-A6 cells were plated in six-well culture plates at a density of 7000 cells per well and treated with 
50µg/ml and 100µg/ml cetuximab for four days as indicated. Then cells were fixed and stained. One photo/well 
was taken to document the density of colony formation in the wells. (B) 10 images/well were randomly taken 
using the P.A.L.M. DuoFlex Combi System (Carl Zeiss). The arrows indicate colonies composed of 50 cells or 
more, while arrowheads point at colonies of less than 50 cells. (C-E) Colonies of 50, 40, and 30 cells or more 
were counted in 10 images/condition and plotted against cetuximab concentrations. The error bars represent the 
SD. Statistical analysis was performed using student’s unpaired t-test and based on the analysis of 10 
images/well that were randomly taken of the same experiment. * represent a significant decrease of colony 
formation compared to A431wt control; * P < 0.05, ** P< 0.01, *** P < 0.001. (n = 1). 
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3.7 Cell growth inhibition of AnxA6 expressing cells treated 
with cetuximab 
The results presented in section  3.6 indicated the increased efficacy of cetuximab in A431-A6 
cells. To substantiate these findings, MTS assays were performed in which A431wt and 
A431-A6 cells were seeded at a density of 4000 cells per well, and incubated with different 
cetuximab concentrations (2.5µM, 10µM, and 20µM) for three days. Quadruple repeats were 
made for each treatment. Then, MTS reagent was added and the plates were incubated for 30 
minutes. The absorbance was detected at 490 nm, and the percentage of growth inhibition 
was calculated and plotted against cetuximab concentrations. The results showed 0.4% 
growth inhibition in A431wt cells compared to 4.6% in A431-A6 cells with 2.5µM 
cetuximab. 10µM of the drug caused 2.5% and 5.5% growth inhibition in A431wt and A431-
A6 cells, respectively. Finally, 20µM cetuximab led to 10.8% and 18% growth inhibition in 
A431wt and A431-A6 cells, respectively (Figure 14). These results, in support of the data 
obtained from clonogenic assays (Figure 13), show a trend that A431-A6 cells are more 
sensitive to cetuximab than A431wt cells. 
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Figure 14. MTS assay showing the effect of cetuximab on A431wt and A431-A6 cell growth. A431wt and 
A431-A6 cells were seeded at a density of 4000 cells per well and incubated with 2.5µM, 10µM, and 20µM 
cetuximab for three days. Quadruple repeats were made for each treatment. Then, MTS reagent was added and 
the plates were incubated for 30 minutes. The absorbance was detected at 490 nm, and the percentage of growth 
inhibition was calculated and plotted against cetuximab concentrations. The error bars represent the SD (n = 1). 
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3.8 PD98059 increases growth inhibition of A431-A6 cells 
Aberrant EGFR signaling leads to enhanced oncogenic activity of the Ras/MAPK pathway. 
Small molecules inhibiting MEK1/2 are potent anti-cancer drugs blocking the subsequent 
ERK activation and inhibiting the growth-promoting signaling cascade (120). AnxA6 was 
found to inhibit not only EGFR, but also Ras activation (22). We wanted to explore if this 
potential tumor suppressor activity of AnxA6 could increase the potency of MEK1/2 
inhibitors. Therefore, the clonogenic assay was employed to study the inhibitory effect of the 
MEK1/2 inhibitor PD98059 on the oncogenic growth of A431wt and A431-A6 cells. A431wt 
and A431-A6 cells were incubated with 1µM and 25µM PD98059 for five days to allow 
colony formation. PD98059 is commonly used at 10-25µM concentrations in cell culture 
assays to ensure MEK1/2 inactivation (238). Then, the cells were washed twice with DPBS, 
fixed and stained. To avoid overlooking growth-inhibitory effects of AnxA6 occurring at 
later stages of colony growth, colonies of twenty, thirty, forty and fifty cells or more were 
counted and plotted against PD98059 concentrations (Figure 15). Taking into consideration 
colonies of fifty cells or more, A431-A6 control had 7.1% less colony formation than A431wt 
control which is a decrease from 42 ± 1.9 to 39 ± 3.5. When cells were treated with 1µM 
PD98059, colony formation was unexpectedly increased by 21% in A431wt cells (51 ± 2.0), 
while decreased by 45.2% in A431-A6 cells (23 ± 2.5). 25µM PD98059 treatment inhibited 
colony formation in A431wt cells by 33.3% (28 ± 1.5), and by 76.2% (10 ± 1.2) in A431-A6 
cells (Figure 15C). Similar trends were observed when we quantified the counts from 
colonies with 20, 30, 40 cells or more (Figure 15). Hence, similar to the data obtained with 
EGFR inhibitors, blocking oncogenic MAPK signaling was also substantially more effective 
upon AnxA6 overexpression. 
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Figure 15. Clonogenic assay of A431wt and A431-A6 cells treated with 0-25µM PD98059. (A) A431wt and 
A431-A6 cells were plated in six-well culture plates at a density of 7000 cells per well and treated with 1µM 
and 25µM PD98059 for five days as indicated. Then cells were fixed and stained. One photo/well was taken to 
document the density of colony formation in the wells. (B) 10 images/well were randomly taken using the 
P.A.L.M. DuoFlex Combi System (Carl Zeiss). The arrows indicate colonies composed of 50 cells or more, 
while arrowheads point at colonies of less than 50 cells. (C-F) Colonies of 50, 40, 30, and 20 cells or more were 
counted in 10 images/condition and plotted against PD98059 concentrations. The error bars represent the SD. 
Statistical analysis was performed using student’s unpaired t-test and based on the analysis of 10 images/well 
that were randomly taken of the same experiment. * represent a significant decrease of colony formation 
compared to A431wt control; * P < 0.05, ** P< 0.01, *** P < 0.001. 
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3.9 Combinatorial treatment with erlotinib and PD98059 
potently inhibits oncogenic growth of A431 cells 
Elevated expression of AnxA6 was associated with increased sensitivity towards drugs 
targeting EGFR and MAPK (sections  3.1- 3.8). Given that combinatorial treatment is now 
widely considered as a more effective approach to treat cancers (202-204), we wanted to 
investigate if AnxA6 could lead to an increased potency upon treating A431 cells with both 
TKI and MEK1/2 inhibitor simultaneously. Therefore, clonogenic assays were performed to 
study the inhibitory effect of erlotinib, PD98059, and their combination on the oncogenic 
growth of A431wt and A431-A6 cells. Both cell lines were incubated with 1µM erlotinib, 
25µM PD98059, and a combination of both drugs for five days to allow colony formation. 
Then, the cells were washed twice with DPBS, fixed and stained. To avoid overlooking 
growth-inhibitory effects of AnxA6 occurring at later stages of colony growth, colonies of 
twenty, thirty, forty and fifty cells or more were counted and plotted against the drug 
treatments (Figure 16 and 17).  
The identification of colonies of fifty cells or more revealed that A431-A6 control had 22.9% 
less colony formation than A431wt control. When 1µM erlotinib was applied, the number of 
colonies significantly decreased in A431wt and A431-A6 cells (27.5 ± 1.2 and 8.5 ± 3.7) 
which reflects 65% and 89.1% inhibition, respectively (P < 0.05). The use of 25µM PD98059 
was able to decrease the number of colonies to 66.5 ± 8.6 and 45 ± 9 in A431wt and A431-
A6 cells which is 15.3% and 42.7% inhibition, respectively. These results confirm our 
previous findings discussed earlier (sections 4.1-4.5, 4.8). In addition, when 1µM erlotinib 
and 25µM PD98059 were used together as a combinatorial treatment, the number of colonies 
was significantly decreased to 14 ± 6.5 and 3.5 ± 2 in A431wt and A431-A6 cells, which 
represents 82.2% (P < 0.05) and 95.5% (P < 0.01) growth inhibition, respectively (Figure 17 
A-C). Similar trends were observed when we quantified the counts from colonies with 20, 30, 
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40 cells or more (Figure 17). Hence, the combinatorial drug treatment was able to effectively 
reduce colony formation in A431 cells compared to single drug treatments. Moreover, the 
results indicated that the combination of both TKI and MEK1/2 inhibitor potently inhibited 
growth more effectively in the presence of AnxA6. 
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Figure 16. Clonogenic assay of A431 cells treated with 1µM erlotinib and 25µM PD98059 alone or in 
combination. (A) A431wt and A431-A6 cells were plated in six-well culture plates at a density of 7000 cells 
per well and incubated with 1µM erlotinib, 25µM PD98059, and a combination of both drugs for five days as 
indicated. Then cells were fixed and stained. One photo/well was taken to document the density of colony 
formation in the wells. (B) 10 images/well were randomly taken using the P.A.L.M. DuoFlex Combi System 
(Carl Zeiss). The arrows indicate colonies composed of 50 cells or more, while arrowheads point at colonies of 
less than 50 cells. (C-F) Colonies of 50, 40, 30, and 20 cells or more were counted in 10 images/condition and 
plotted against drug treatments. The error bars represent the SD. Statistical analysis was performed using 
student’s unpaired t-test and based on the analysis of 10 images/well that were randomly taken of the same 
experiment. * represents a significant decrease of colony formation compared to A431wt control; * P < 0.05, ** 
P< 0.01, *** P < 0.001. 
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Figure 17. The inhibitory effect of erlotinib, PD98059, and their combination on A431wt and A431-A6 
colony growth. A431wt and A431-A6 cells were incubated with 1µM erlotinib, 25µM PD98059, and a 
combination of both drugs for five days. Colonies of 20, 30, 40, and 50 cells or more were counted. Data 
represents the mean ± SEM of two independent experiments. (A, D, G, J) The number of colonies of A431wt 
and A431-A6 were plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, 
respectively. (B, E, H, K) The number of colonies of A431wt and A431-A6 were normalized to A431wt control 
and A431-A6 control, respectively, and plotted against drug treatments where each colony is 50, 40, 30, 20 cells 
or more, respectively. (C, F, I, L) The number of colonies of A431wt and A431-A6 were normalized to A431wt 
control and plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. 
Statistical analysis was performed using student’s unpaired t-test where * represents a significant decrease of 
colony formation compared to A431wt control; * P < 0.05, ** P < 0.01.  
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3.10 Potent growth inhibition in A431 cells treated with gefitinib 
together with PD98059 
To extend our previous finding (section  3.9) that A431-A6 cells displayed an increased 
sensitivity towards the combinatorial treatment with TKI and MEK1/2 inhibitors, we next 
compared colony formation in A431wt and A431-A6 cells treated with gefitinib and 
PD98059 alone or in combination. A431wt and A431-A6 cells were incubated with 1µM 
gefitinib, 25µM PD98059, and a combination of both drugs for five days to allow colony 
formation. Then, the cells were washed twice with DPBS, fixed and stained. To avoid 
overlooking growth-inhibitory effects of AnxA6 occurring at later stages of colony growth, 
colonies of twenty, thirty, forty and fifty cells or more were counted and plotted against drug 
treatments (Figure 18 and 19).  
Taking into consideration colonies of fifty cells or more, A431-A6 control had 22.9% less 
colonies than A431wt control. When 1µM gefitinib was applied, the number of colonies 
significantly decreased in A431wt and A431-A6 cells (36 ± 4.9 and 10.5 ± 5.3), which 
reflects an inhibition of 54.1% and 86.6%, respectively (P < 0.05). The use of 25µM 
PD98059 decreased the number of colonies in A431wt and A431-A6 cells (66.5 ± 8.6 and 45 
± 9) by 15.3% and 42.7%, respectively. In line with data shown in section  3.9, when 1µM 
gefitinib and 25µM PD98059 were used together, the number of colonies decreased in 
A431wt cells by 72.6%, and significantly decreased in A431-A6 by 97.5% (P < 0.01) (Figure 
19A-C). Similar trends were observed when we quantified the counts from colonies with 20, 
30, 40 cells or more (Figure 19). Hence, the combinatorial treatment with TKI and MEK1/2 
inhibitors was more effective in A431-A6 cells compared to A431wt cells. 
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Figure 18. Clonogenic assay of A431 cells treated with 1µM gefitinib and 25µM PD98059 alone or in 
combination. (A) A431wt and A431-A6 cells were plated in six-well culture plates at a density of 7000 cells 
per well and incubated with 1µM erlotinib, 25µM PD98059, and a combination of both drugs for five days as 
indicated. Then cells were fixed and stained. One photo/well was taken to document the density of colony 
formation in the wells. (B) 10 images/well were randomly taken using the P.A.L.M. DuoFlex Combi System 
(Carl Zeiss). The arrows indicate colonies composed of 50 cells or more, while arrowheads point at colonies of 
less than 50 cells. (C-F) Colonies of 50, 40, 30, and 20 cells or more were counted in 10 images/condition and 
plotted against drug treatments. The error bars represent the SD. Statistical analysis was performed using 
student’s unpaired t-test and based on the analysis of 10 images/well that were randomly taken of the same 
experiment. * represents a significant decrease of colony formation compared to A431wt control; * P < 0.05, ** 
P< 0.01, *** P < 0.001. 
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Figure 19. The inhibitory effect of gefitinib, PD98059, and their combination on A431wt and A431-A6 
colony growth. A431wt and A431-A6 cells were incubated with 1µM gefitinib, 25µM PD98059, and a 
combination of both drugs for five days. Colonies of 20, 30, 40, and 50 cells or more were counted. Data 
represents the mean ± SEM of two independent experiments. (A, D, G, J) The number of colonies of A431wt 
and A431-A6 were plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, 
respectively. (B, E, H, K) The number of colonies of A431wt and A431-A6 were normalized to A431wt control 
and A431-A6 control, respectively, and plotted against drug treatments where each colony is 50, 40, 30, 20 cells 
or more, respectively. (C, F, I, L) The number of colonies of A431wt and A431-A6 were normalized to A431wt 
control and plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. 
Statistical analysis was performed using student’s unpaired t-test where * represents a significant decrease of 
colony formation compared to A431wt control; * P < 0.05, ** P < 0.01. 
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3.11 The anti-cancer effects in AnxA6 expressing cells treated 
with the combination of erlotinib and cetuximab  
As discussed in section  1.6.2, cetuximab and erlotinib are two EGFR inhibitors that perform 
their actions via two different mechanisms. We studied the effect of each drug alone on the 
oncogenic proliferation of A431 cells and found more effective inhibition upon AnxA6 
overexpression (sections  3,  3.2,  3.6,  3.7). Some strategies suggested that combining small 
molecules such as TKIs with mAbs targeting EGFR could be more effective (237). Hence, 
we wanted to test the effect of combining the two drugs together and identify if an increased 
growth inhibition could be observed upon AnxA6 overexpression in A431 cells. Clonogenic 
assays were performed in which A431wt and A431-A6 cells were incubated with 1µM 
erlotinib, 50µg/ml cetuximab, and a combination of both drugs for five days. Then, the cells 
were washed twice with DPBS, fixed and stained. To avoid overlooking growth-inhibitory 
effects of AnxA6 occurring at later stages of colony growth, colonies of twenty, thirty, forty 
and fifty cells or more were counted and plotted against drug treatments (Figure 20).  
When colonies of fifty cells or more were counted, A431-A6 control had 54.3% less colony 
formation than A431wt control. When 1µM erlotinib was applied, the number of colonies 
decreased in A431wt and A431-A6 cells to 9 ± 0.7 and 7 ± 0.7, which reflects 74.3% and 
80% inhibition, respectively. When 50µg/ml cetuximab was applied alone as a single drug, 
the number of colonies became 36 ± 2 and 28 ± 1.8 in A431wt and A431-A6 cells, 
respectively, which represents an increase of colony formation by 2.9% in A431wt cells and a 
decrease of colony formation by 20% in A431-A6 cells.  
However, treating the cells with the combination of 1µM erlotinib and 50µg/ml cetuximab 
led to a decrease of the number of colonies to 19 ± 1.4 and 13 ± 1.3 in A431wt and A431-A6 
cells, that is 45.7% and 62.9% growth inhibition, respectively (Figure 20C). Similar trends 
were observed when we quantified the counts from colonies with 20, 30, 40 cells or more 
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(Figure 20). The results showed that the inhibition of colony formation was always more 
pronounced in A431-A6 cells as compared to A431wt cells in all settings. Although 
published data reports cetuximab to inhibit A431wt cell growth (233, 234), cetuximab did not 
strongly affect A431wt colony formation in our experiment (Figure 20). Moreover, the 
presence of cetuximab reduced the efficacy of erlotinib in both A431wt and A431-A6 cells. 
This observation could be due to competition of anti-EGFR agents, or possibly reflects the 
possibility that our batch of A431 cells had developed resistance to cetuximab, a phenomena 
also observed by others (239, 240). 
3.12 The combination of gefitinib and cetuximab potentiates the 
inhibition of colony formation in A431 cells 
The results obtained using a combination of erlotinib and cetuximab in section  3.11 directed 
us to try using another TKI, together with the monoclonal antibody cetuximab, in order to 
compare the cellular oncogenic growth in cells with and without AnxA6 overexpression. 
Clonogenic assays were adopted using A431wt and A431-A6 cells that were incubated with 
1µM gefitinib, 50µg/ml cetuximab, and a combination of both drugs for five days. Then, the 
cells were washed twice with DPBS, fixed and stained. To avoid overlooking growth-
inhibitory effects of AnxA6 occurring at later stages of colony growth, colonies of twenty, 
thirty, forty and fifty cells or more were counted and plotted against drug treatments (Figure 
21).  
When colonies of fifty cells or more were identified, the results showed 54.3% less colony 
formation in A431-A6 cells compared to A431wt cells. 1µM gefitinib reduced the number of 
colonies in A431wt and A431-A6 cells by 82.9% and 88.6%, respectively. The number of 
colonies became 36 ± 2 and 28 ± 1.8 in A431wt and A431-A6 cells, respectively, when 
50µg/ml cetuximab was used alone as a single drug which represents an increase of colony 
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formation by 2.9% in A431wt cells and a decrease of colony formation in A431-A6 cells by 
20%. Nevertheless, when 1µM gefitinib and 50µg/ml cetuximab were combined together, the 
number of colonies became 10 ± 1.1 and 6 ± 0.7 in A431wt and A431-A6 cells which 
represents 71.4% and 82.9% growth inhibition, respectively (Figure 21C). Similar trends 
were observed when we quantified the counts from colonies with 20, 30, 40 cells or more 
(Figure 21). These results showed that effective growth inhibition was noted with the 
combinatorial treatment of cetuximab and gefitinib compared to cetuximab alone. However, 
these numbers were similar to those obtained from the incubation of gefitinib alone; 
supporting our previous findings (Figure 20) that cetuximab did not potentiate the growth 
inhibitory action of TKIs under our experimental conditions.  
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Figure 20. Clonogenic assay of A431 cells treated with 1µM erlotinib and 50µg/ml cetuximab alone or in 
combination. (A) A431wt and A431-A6 cells were plated in six-well culture plates at a density of 7000 cells 
per well and incubated with 1µM erlotinib, 50µg/ml cetuximab, and a combination of both drugs for five days 
as indicated. Then cells were fixed and stained. One photo/well was taken to document the density of colony 
formation in the wells. (B) 10 images/well were randomly taken using the P.A.L.M. DuoFlex Combi System 
(Carl Zeiss). The arrows indicate colonies composed of 50 cells or more, while arrowheads point at colonies of 
less than 50 cells. (C-F) Colonies of 50, 40, 30, and 20 cells or more were counted in 10 images/condition and 
plotted against drug treatments. The error bars represent the SD. Statistical analysis was performed using 
student’s unpaired t-test and based on the analysis of 10 images/well that were randomly taken of the same 
experiment. * represents a significant decrease of colony formation compared to A431wt control; * P < 0.05, ** 
P< 0.01, *** P < 0.001.                                                                         
63 
 
                                                                           (A) 
 
                                                                           (B) 
 
                                          
C o n tro l 1 µ M  G e fit in ib 5 0 µ g /m l 
C e tu x im a b
1 µ M  G e fit in ib
+  
5 0 µ g /m l 
C e tu x im a b
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
C o lo n ie s  h a v e   3 0  c e lls  / c o lo n y
D ru g  tre a tm e n t (µ M )
N
u
m
b
e
r
 o
f 
c
o
lo
n
ie
s
A 4 3 1w t
A 4 3 1 -A 6
***
***
***
***
***
*
*
C o n tro l 1 µ M  G e fit in ib 5 0 µ g /m l 
C e tu x im a b
1 µ M  G e fit in ib
+  
5 0 µ g /m l 
C e tu x im a b
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
1 2 0
1 3 0
1 4 0
C o lo n ie s  h a v e   2 0  c e lls  / c o lo n y
D ru g  tre a tm e n t (µ M )
N
u
m
b
e
r
 o
f 
c
o
lo
n
ie
s
A 4 3 1w t
A 4 3 1 -A 6
***
***
***
***
***
*
C o n tro l 1 µ M  G e fit in ib 5 0 µ g /m l 
C e tu x im a b
1 µ M  G e fit in ib
+  
5 0 µ g /m l 
C e tu x im a b
0
1 0
2 0
3 0
4 0
C o lo n ie s  h a v e   5 0  c e lls  / c o lo n y
D ru g  tre a tm e n t (µ M )
N
u
m
b
e
r
 o
f 
c
o
lo
n
ie
s
A 4 3 1w t
A 4 3 1 -A 6
***
***
***
***
**
C o n tro l 1 µ M  G e fit in ib 5 0 µ g /m l 
C e tu x im a b
1 µ M  G e fit in ib
+  
5 0 µ g /m l 
C e tu x im a b
0
1 0
2 0
3 0
4 0
5 0
6 0
C o lo n ie s  h a v e   4 0  c e lls  / c o lo n y
D ru g  tre a tm e n t (µ M )
N
u
m
b
e
r
 o
f 
c
o
lo
n
ie
s
A 4 3 1w t
A 4 3 1 -A 6
***
***
***
***
***
*
(C ) (D )
(E ) (F )
 
Figure 21. Clonogenic assay of A431 cells treated with 1µM gefitinib and 50µg/ml cetuximab alone or in 
combination. (A) A431wt and A431-A6 cells were plated in six-well culture plates at a density of 7000 cells 
per well and incubated with 1µM gefitinib, 50µg/ml cetuximab, and a combination of both drugs for five days 
as indicated. Then cells were fixed and stained. One photo/well was taken to document the density of colony 
formation in the wells. (B) 10 images/well were randomly taken using the P.A.L.M. DuoFlex Combi System 
(Carl Zeiss). The arrows indicate colonies composed of 50 cells or more, while arrowheads point at colonies of 
less than 50 cells. (C-F) Colonies of 50, 40, 30, and 20 cells or more were counted in 10 images/condition and 
plotted against drug treatments. The error bars represent the SD. Statistical analysis was performed using 
student’s unpaired t-test and based on the analysis of 10 images/well that were randomly taken of the same 
experiment. * represents a significant decrease of colony formation compared to A431wt control; * P < 0.05, ** 
P< 0.01, *** P < 0.001, (n = 1). 
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3.13 Potent inhibition of colony formation in AnxA6 expressing 
cells treated with the combination of erlotinib and Gö 6976 
The benefits of combinatorial therapies in treating complex diseases like cancer are now 
evident (202-204). We tested the targeted approach of combining TKIs with not only 
MEK1/2 inhibitor, but also mAb in cells overexpressing AnxA6 (sections  3.9-  3.12). Grewal 
and coworkers showed that AnxA6 inhibited EGFR signaling via PKCα-dependent pathways 
(29). Therefore, we next aimed at identifying the effect of combining a TKI with a PKCα 
inhibitor on the oncogenic cell proliferation of A431 cells. Clonogenic assays were adapted in 
this regards and Gö 6976, a selective inhibitor of PKCα, was used. In these assays, A431wt 
and A431-A6 cells were incubated with 1µM erlotinib, 1µM Gö 6976, and a combination of 
both drugs for five days to allow colony formation. Then, the cells were washed twice with 
DPBS, fixed and stained. To avoid overlooking growth-inhibitory effects of AnxA6 
occurring at later stages of colony growth, colonies of twenty, thirty, forty and fifty cells or 
more were counted and plotted against drug treatments (Figure 22 and 23).  
Taking into account colonies of fifty cells or more, A431-A6 control had 45.3% less colony 
formation than A431wt control. When a single drug treatment was applied to the A431wt 
cells, the number of colonies significantly decreased with 1µM erlotinib to 12 ± 0.6, and with 
1µM Gö 6976 to 26.7 ± 10, which represents 71.9% and 37.5% growth inhibition, 
respectively. In A431-A6 cells, the number of colonies were reduced to 3 ± 1 with 1µM 
erlotinib and to 12 ± 2.6 with 1µM Gö 6976, which reflects 93% and 71.9% growth 
inhibition, respectively (P<0.05).  
Furthermore, the combinatorial treatment of 1µM erlotinib and 1µM Gö 6976 significantly 
reduced the number of colonies to 5.3 ± 2 and 0.7 ± 0.3 in A431wt and A431-A6 cells which 
represents 87.5% and 98.4% growth inhibition, respectively (P<0.05) (Figure 23A-C). 
Similar trends were observed when we quantified the counts from colonies with 20, 30, 40 
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cells or more (Figure 23). The experiment was repeated three times and displayed a weak 
inhibition of growth when Gö 6976 was used alone as a single agent. This may reflect the 
controversial results obtained in other studies regarding the use of PKC inhibitors in cancer 
(41). Although PKCα knockdown restored EGFR activity in A431-A6 cells in another study 
(29), we observed that the combinatorial targeted therapy of erlotinib and Gö 6976 together 
displayed a potent inhibition of cell growth especially in A431-A6 cells. We speculate that 
Gö 6976 might act through an inhibition of other key regulators in cell proliferation, which 
will be discussed further below (chapter 4). 
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Figure 22. Clonogenic assay of A431 cells treated with 1µM erlotinib and 1µM Gö 6976 alone or in 
combination. (A) A431wt and A431-A6 cells were plated in six-well culture plates at a density of 7000 cells 
per well and incubated with 1µM erlotinib, 1µM Gö 6976, and their combination for five days as indicated. 
Then cells were fixed and stained. One photo/well was taken to document the density of colony formation in the 
wells. (B) 10 images/well were randomly taken using the P.A.L.M. DuoFlex Combi System (Carl Zeiss). The 
arrows indicate colonies composed of 50 cells or more, while arrowheads point at colonies of less than 50 cells. 
(C-F) Colonies of 50, 40, 30, and 20 cells or more were counted in 10 images/condition and plotted against drug 
treatments. The error bars represent the SD. Statistical analysis was performed using student’s unpaired t-test 
and based on the analysis of 10 images/well that were randomly taken of the same experiment. * represents a 
significant decrease of colony formation compared to A431wt control; * P < 0.05, ** P< 0.01, *** P < 0.001. 
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Figure 23. The inhibitory effect of erlotinib, Gö 6976, and their combination on A431wt and A431-A6 
colony formation. A431wt and A431-A6 cells were incubated with 1µM erlotinib, 1µM Gö 6976, and a 
combination of both drugs for five days. Colonies of 20, 30, 40, and 50 cells or more were counted. Data 
represents the mean ± SEM of three independent experiments. (A, D, G, J) The number of colonies of A431wt 
and A431-A6 were plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, 
respectively. (B, E, H, K) The number of colonies of A431wt and A431-A6 were normalized to A431wt control 
and A431-A6 control, respectively, and plotted against drug treatments where each colony is 50, 40, 30, 20 cells 
or more, respectively. (C, F, I, L) The number of colonies of A431wt and A431-A6 were normalized to A431wt 
control and plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. 
Statistical analysis was performed using student’s unpaired t-test where * represents a significant decrease of 
colony formation compared to A431wt control; * P < 0.05, ** P < 0.01, *** P < 0.001.  
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3.14 Enhanced anti-cancer properties of the combinatorial use of 
gefitinib and Gö 6976 in A431-A6 cells 
As we found that AnxA6 increases the sensitivity of A431 cells towards the combinatorial 
treatment of erlotinib and Gö 6976 (section  3.13), we followed this finding by another 
experiment in which we examined a combination of gefitinib and Gö 6976 in clonogenic 
assays. Therefore, A431wt and A431-A6 cells were incubated with 1µM gefitinib, 1µM Gö 
6976, and a combination of both drugs for five days to allow colony formation. Then, the 
cells were washed twice with DPBS, fixed and stained. To avoid overlooking growth-
inhibitory effects of AnxA6 occurring at later stages of colony growth, colonies of twenty, 
thirty, forty and fifty cells or more were counted and plotted against drug treatments (Figure 
24 and 25).  
Counting colonies of fifty cells or more showed that A431-A6 control had 45.3% less colony 
formation than A431wt control. When a single drug treatment of 1µM gefitinib and 1µM Gö 
6976 was applied to the A431wt cells, the number of colonies decreased to 16 ± 2.3, and 26.7 
± 10 that is 61% and 37.5% growth inhibition, respectively. In A431-A6 cells, 95.3% (2 ± 
0.6) and 71.9% (12 ± 2.6) growth inhibition (P<0.05) was identified when the cells were 
treated with 1µM gefitinib and 1µM Gö 6976, respectively. Finally, using the combinatorial 
treatment of 1µM gefitinib and 1µM Gö 6976 lead to 97.7% (1 ± 0.6) growth and colony 
inhibition in both cell lines (P<0.05) (Figure 25A-C). Similar trends were observed when we 
quantified the counts from colonies with 20, 30, 40 cells or more (Figure 25). The experiment 
was repeated three times, and the results supported our previous finding that the combination 
of TKI and PKC inhibitor was more effective in reducing oncogenic cell growth in A431 
cells than using the individual drugs. Furthermore, when counting colonies with 20 or 30 
cells or more, the combinatorial use of gefitinib and Gö 6976 were more effective in 
inhibiting colony formation in A431-A6 cells as compared to A431wt cells (Figure 25 G-L).                                                                         
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Figure 24. Clonogenic assay of A431 cells treated with 1µM gefitinib and 1µM Gö 6976 alone or in 
combination. (A) A431wt and A431-A6 cells were plated in six-well culture plates at a density of 7000 cells 
per well and incubated with 1µM gefitinib, 1µM Gö 6976, and a combination of both drugs for five days as 
indicated. Then cells were fixed and stained. One photo/well was taken to document the density of colony 
formation in the wells. (B) 10 images/well were randomly taken using the P.A.L.M. DuoFlex Combi System 
(Carl Zeiss). The arrows indicate colonies composed of 50 cells or more, while arrowheads point at colonies of 
less than 50 cells. (C-F) Colonies of 50, 40, 30, and 20 cells or more were counted in 10 images/condition and 
plotted against drug treatments. The error bars represent the SD. Statistical analysis was performed using 
student’s unpaired t-test and based on the analysis of 10 images/well that were randomly taken of the same 
experiment. * represents a significant decrease of colony formation compared to A431wt control; * P < 0.05, ** 
P< 0.01, *** P < 0.001. 
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Figure 25. The inhibitory effect of gefitinib, Gö 6976, and their combination on A431wt and A431-A6 cell 
growth. A431wt and A431-A6 cells were incubated with 1µM gefitinib, 1µM Gö 6976, and a combination of 
both drugs for five days. Colonies of 20, 30, 40, and 50 cells or more were counted. Data represents the mean ± 
SEM of three independent experiments. (A, D, G, J) The number of colonies of A431wt and A431-A6 were 
plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. (B, E, H, K) The 
number of colonies of A431wt and A431-A6 were normalized to A431wt control and A431-A6 control, 
respectively, and plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. 
(C, F, I, L) The number of colonies of A431wt and A431-A6 were normalized to A431wt control and plotted 
against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. Statistical analysis was 
performed using student’s unpaired t-test where * represents a significant decrease of colony formation 
compared to A431wt control; * P < 0.05, ** P < 0.01, *** P < 0.001.  
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3.15 The effect of BIM-I on A431 cell growth in MTS assays. 
Besides Gö 6976, BIM-I is a potent inhibitor commonly used to block the conventional PKC 
enzymes via targeting the ATP-binding site of the kinase catalytic domain. We employed 
BIM-I in our MTS assay to investigate the effect of AnxA6 upregulation on A431 cell 
growth. A431wt and A431-A6 cells were seeded at a density of 4000 cells per well, and 
incubated with different concentrations of the drug (0.1µM, 0.5µM, 1µM) for three days. 
Quadruple repeats were made for each treatment. Then MTS reagent was added and the 
plates were incubated for 30 minutes. The absorbance was detected at 490 nm, and the 
percentage of viability was calculated and plotted against BIM-I concentrations. The results 
showed a percentage of viability of 101.4%, 105.4%, and 100.2% in A431wt cells treated 
with 0.1µM, 0.5µM, and 1µM BIM-I, respectively. In A431-A6 cells, the percentage of 
viability was 98%, 165.6%, and 148.4% with 0.1µM, 0.5µM, and 1µM BIM-I treatments, 
respectively (Figure 26). Hence, the oncogenic growth in A431-A6 and A431wt cells was not 
negatively affected by employing an inhibitor of conventional PKC enzymes. 
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Figure 26. MTS assay showing the effect of BIM-I on A431wt and A431-A6 cell growth. A431wt and 
A431-A6 cells were seeded at a density of 4000 cells per well, and incubated with 0.1µM, 0.5µM and 1µM 
BIM-I for three days. Quadruple repeats were made for each treatment. Then MTS reagent was added and the 
plates were incubated for 30 minutes. The absorbance was detected at 490 nm, and the percentage of viability 
was calculated and plotted against BIM-I concentrations. The error bars represent the SD (n = 1). 
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3.16 Combinatorial use of erlotinib and BIM-I potentiates growth 
inhibition in A431 cells 
The combinatorial treatment of TKIs with Gö 6976 potentiated growth inhibition in A431 
cells that was more in A431-A6 cells compared to A431wt cells (sections  3.13 and  3.14). To 
extend these findings, we tested the ability of BIM-I, a potent inhibitor of the conventional 
PKC isozymes, in combination with erlotinib in clonogenic assays. The cells were incubated 
with 1µM erlotinib, 1µM BIM-I, and a combination of both drugs for five days to allow 
colony formation. Then, cells were washed twice with DPBS, fixed and stained. To avoid 
overlooking growth-inhibitory effects of AnxA6 occurring at later stages of colony growth, 
colonies of twenty, thirty, forty and fifty cells or more were counted and plotted against drug 
treatments (Figure 27 and 28).  
After the quantification of colonies of fifty cells or more, we found that A431-A6 control had 
71% less colony formation than A431wt control. Treating A431wt and A431-A6 cells with 
1µM erlotinib reduced the number of colonies to 13.5 ± 1.5 and 5.5 ± 1.5, which is 70.3% 
and 87.9% inhibition, respectively. In contrast, the application of 1µM BIM-I did not 
significantly affect the colony growth in either A431wt cells or A431-A6 cells. The 
combinatorial treatment of 1µM erlotinib and 1µM BIM-I decreased the number of colonies 
to 11.5 ± 3.5 and 1.5 ± 0.5 in A431wt and A431-A6 cells, which represents 74.7% and 96.7% 
growth inhibition, respectively (Figure 28A-C). Similar trends were observed when we 
quantified the counts from colonies with 20, 30, 40 cells or more (Figure 28). The experiment 
was repeated twice and the results supported our MTS data (Figure 26) in that BIM-I, as a 
single agent, did not significantly modulate the cell growth of any of the two cell lines. 
However, when BIM-I was combined with erlotinib, the cell growth was effectively 
inhibited, particularly in A431-A6 cells. As mentioned above (section  3.15), these findings 
were unexpected and did not correlate well with the data obtained from PKC knockdown 
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studies performed by Grewal and coworkers previously (29). This will be discussed in more 
details in the discussion chapter. 
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Figure 27. Clonogenic assay of A431 cells treated with 1µM erlotinib and 1µM BIM-I as single or 
combinatorial treatments. (A) A431wt and A431-A6 cells were plated in six-well culture plates at a density of 
7000 cells per well and incubated with 1µM erlotinib, 1µM BIM-I, and a combination of both drugs for five 
days as indicated. Then cells were fixed and stained. One photo/well was taken to document the density of 
colony formation in the wells. (B) 10 images/well were randomly taken using the P.A.L.M. DuoFlex Combi 
System (Carl Zeiss). The arrows indicate colonies composed of 50 cells or more, while arrowheads point at 
colonies of less than 50 cells. (C-F) Colonies of 50, 40, 30, and 20 cells or more were counted in 10 
images/condition and plotted against drug treatments. The error bars represent the SD. Statistical analysis was 
performed using student’s unpaired t-test and based on the analysis of 10 images/well that were randomly taken 
of the same experiment. * represents a significant decrease of colony formation compared to A431wt control; * 
P < 0.05, ** P< 0.01, *** P < 0.001. 
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Figure 28. The inhibitory effect of erlotinib, BIM-I, and their combination on A431wt and A431-A6 cell 
proliferation. A431wt and A431-A6 cells were incubated with 1µM erlotinib, 1µM BIM-I, and a combination 
of both drugs for five days. Colonies of 20, 30, 40, and 50 cells or more were counted. Data represents the mean 
± SEM of two independent experiments. (A, D, G, J) The number of colonies of A431wt and A431-A6 were 
plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. (B, E, H, K) The 
number of colonies of A431wt and A431-A6 were normalized to A431wt control and A431-A6 control, 
respectively, and plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. 
(C, F, I, L) The number of colonies of A431wt and A431-A6 were normalized to A431wt control and plotted 
against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. Statistical analysis was 
performed using student’s unpaired t-test where * represents a significant decrease of colony formation when 
comparing the number of colonies formed by A431wt and A431-A6 cells that were treated with the same drug 
treatments; * P < 0.05, ** P < 0.01.  
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3.17 Combinatorial treatment of gefitinib and BIM-I enhanced 
growth inhibition in AnxA6 expressing cells 
After observing the inhibition of A431wt and A431-A6 growth upon exposure to a 
combination of erlotinib and BIM-I, we next moved to test another TKI combined with BIM-
I via clonogenic assays. 1µM gefitinib, 1µM BIM-I, and a combination of both drugs were 
applied to A431wt and A431-A6 cells followed by five days incubation to allow colony 
formation. Then the cells were washed twice with DPBS, fixed and stained. To avoid 
overlooking growth-inhibitory effects of AnxA6 occurring at later stages of colony growth, 
colonies of twenty, thirty, forty and fifty cells or more were counted and plotted against drug 
treatments (Figure 29 and 30).  
Colonies of fifty cells or more in both cell lines showed that A431-A6 control had 71% less 
colony formation than A431wt control. When 1µM gefitinib was applied, the number of 
colonies significantly decreased in A431wt and A431-A6 cells to 18.5 ± 1.5 and 4.5 ± 1.5, 
which reflects 59.3% and 90.1% inhibition, respectively (P< 0.05). The use of 1µM BIM-I 
was able to marginally decrease the number of colonies to 43 ± 13 (5.5%) and 38 ± 5 (16.5%) 
in A431wt and A431-A6 cells, respectively.  
On the other hand, when 1µM gefitinib and 1µM BIM-I were used together as a 
combinatorial treatment, the number of colonies was significantly decreased to 8.5 ± 0.5 and 
1.5 ± 0.5 in A431wt and A431-A6 cells which represents 81.3% and 96.7% growth 
inhibition, respectively  (P < 0.05) (Figure 30A-C). Similar trends were observed when we 
quantified the counts from colonies with 20, 30, 40 cells or more (Figure 30).The experiment 
was repeated twice, and the results supported our previous findings (sections  3.13,  3.14, and 
 3.16) of the enhanced growth inhibition observed when a TKI is combined with a selective 
PKC inhibitor in AnxA6 overexpressing cells. 
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Figure 29. Clonogenic assay of A431 cells treated with 1µM gefitinib and 1µM BIM-I alone or in 
combination. (A) A431wt and A431-A6 cells were plated in six-well culture plates at a density of 7000 cells 
per well and incubated with 1µM gefitinib, 1µM BIM-I, and a combination of both drugs for five days as 
indicated. Then cells were fixed and stained. One photo/well was taken to document the density of colony 
formation in the wells. (B) 10 images/well were randomly taken using the P.A.L.M. DuoFlex Combi System 
(Carl Zeiss). The arrows indicate colonies composed of 50 cells or more, while arrowheads point at colonies of 
less than 50 cells. (C-F) Colonies of 50, 40, 30, and 20 cells or more were counted in 10 images/condition and 
plotted against drug treatments. The error bars represent the SD. Statistical analysis was performed using 
student’s unpaired t-test and based on the analysis of 10 images/well that were randomly taken of the same 
experiment. * represents a significant decrease of colony formation compared to A431wt control; * P < 0.05, ** 
P< 0.01, *** P < 0.001. 
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Figure 30. The inhibitory effect of gefitinib, BIM-I, and their combination on the growth of A431wt and 
A431-A6 cells. A431wt and A431-A6 cells were incubated with 1µM gefitinib, 1µM BIM-I, and a combination 
of both drugs for five days. Colonies of 20, 30, 40, and 50 cells or more were counted. Data represents the mean 
± SEM of two independent experiments. (A, D, G, J) The number of colonies of A431wt and A431-A6 were 
plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. (B, E, H, K) The 
number of colonies of A431wt and A431-A6 were normalized to A431wt control and A431-A6 control, 
respectively, and plotted against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. 
(C, F, I, L) The number of colonies of A431wt and A431-A6 were normalized to A431wt control and plotted 
against drug treatments where each colony is 50, 40, 30, 20 cells or more, respectively. Statistical analysis was 
performed using student’s unpaired t-test where * represents a significant decrease of colony formation when 
comparing the number of colonies formed by A431wt and A431-A6 cells that were treated with the same drug 
treatments; * P < 0.05, ** P < 0.01. 
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3.18 Reduced cell growth of AnxA6 expressing cells treated with 
cPLA2 inhibitors 
Grewal and coworkers previously showed that AnxA6 overexpression inhibits caveolae 
formation in a cPLA2-dependant manner (75). Given the inhibitory effects of AnxA6 on the 
EGFR pathway and the role of caveolin-1 and caveolae for EGFR signaling (3, 66, 75, 76), 
we wanted to investigate the oncogenic cell growth of AnxA6 overexpressing cells treated 
with cPLA2 inhibitor. MTS assay was employed in which we treated the cells with MAFP, an 
irreversible inhibitor of cPLA2. A431wt and A431-A6 cells were seeded at a density of 4000 
and 8000 cells per well, and incubated with 5µM and 10µM MAFP for three days. Quadruple 
repeats were made for each treatment. Then, MTS reagent was added and the plates were 
incubated for 30 minutes. The absorbance was detected at 490 nm, and the percentage 
viability was calculated and plotted against MAFP concentrations. When 4000 cells/well 
were treated with 5µM and 10µM MAFP, the viability of the cells was 80.8% and 95.4% in 
A431wt cells, and 77.6% and 77.2% in A431-A6 cells, respectively. While when 8000 
cells/well were treated with 5µM and 10µM MAFP, the viability was 81.3% and 106.4% in 
A431wt cells, and 57.7% and 67.3% in A431-A6 cells, respectively (Figure 31). The results 
showed more reduction of growth in A431-A6 cells compared to A431wt cells treated with 
the same doses of MAFP, and more inhibition was observed with the higher density of cells 
in the wells. These findings could indicate an increased involvement of cPLA2-dependant 
pathways in cell growth in A431-A6 cells. 
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Figure 31. MTS assay showing the effect of MAFP on A431wt and A431-A6 cell growth. A431wt and 
A431-A6 cells were seeded at a density of (A) 4000 and (B) 8000 cells per well, and incubated with 5µM and 
10µM MAFP for three days. Quadruple repeats were made for each treatment. Then, MTS reagent was added 
and the plates were incubated for 30 minutes. The absorbance was detected at 490 nm, and the percentage 
viability was calculated and plotted against MAFP concentrations. The error bars represent the SD. 
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Chapter 4: Discussion 
4.1 Anti-cancer drugs targeting oncogenic EGFR 
Cancer is a complex disease of a multigenic nature. EGFR overexpression or constitutive 
activation, owing to mutations, was found to correlate with the development of different 
types of cancers (241). Hence, blocking the sustained EGFR signaling was crucial to prevent 
tumor growth in these cancers, which led to the discovery of several potential anti-cancer 
agents such as EGFR inhibitors. TKIs and mAbs are the two major categories of EGFR 
inhibitors, terminating the signal via two different mechanisms. TKIs are small molecules 
that compete with ATP for binding to the intracellular tyrosine kinase catalytic domain of 
EGFR, leading to EGFR inhibition. In contrast, mAbs target the extracellular domain of the 
receptor preventing ligand binding, which is followed by EGFR endocytosis and signal 
termination (124, 125). Erlotinib, gefitinib, as examples of TKIs, and cetuximab, as an 
example of mAbs, are among the several FDA approved anti-EGFR drugs which achieved 
clinical success in treating patients with certain types of cancer (126). Despite this success, 
many patients are still unable to benefit from these drugs, a phenomenon that is still not fully 
understood, but could be attributed to inter-patient variation, mutation, and intrinsic/acquired 
resistance (126, 129-135, 138-140, 242). In addition, these drugs face other challenges in 
cancer treatment such as the high dose used and the lack of specificity of some drugs. For 
instance, TKIs target other kinases in addition to EGFR, that can lead to serious side effects 
(243). This justifies the need to identify novel biological markers that could predict the 
treatment outcome in those patients and help making important clinical decisions. 
Some scaffold proteins were suggested as possible biomarkers, for example, the actin binding 
protein cortactin. The amplification of the gene CTTN, which encodes cortactin, was 
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identified in several cancers (244-246). Cortactin overexpression induced a sustained EGFR 
signaling upon attenuation of the receptor downregulation, which was reported to increase 
cell proliferation in HNSCC cells (141, 142). It also decreased the sensitivity towards 
gefitinib in HNSCC cells (141). These findings promoted cortactin as a possible marker for 
the prediction of patients’ response towards EGFR-targeted therapies (141). However, other 
markers with a potential role in cancer still need to be identified. 
4.2 Annexin A6 is a scaffold of the EGFR/Ras/MAPK pathway 
with the potential to increase the efficacy of drugs targeting 
EGFR 
Alternative splicing is known to generate two isoforms of AnxA6 (AnxA6-1, AnxA6-2). The 
two isoforms only differ by 6 amino acids at position 524–529 (VAAEIL). The majority of 
cells and tissues only express the larger AnxA6-1 isoform. This includes skeletal muscle, 
liver, heart, spleen and lymph nodes as well as endothelial and endocrine cells nature, 
secretory epithelia, and macrophages (3). Little is known about the smaller AnxA6-2 isoform, 
which appears abundant in only a few transformed cell lines (94). Most cellular functions, 
including the tumour suppressor activity, have been linked to the larger AnxA6-1 isoform. In 
line with this, Fleet et al (96) reported that AnxA6-1 specifically inhibits the EGF-dependant 
calcium influx in A431 cells transfected with AnxA6 isoforms, and that AnxA6-2 does not 
have observable effect on growth rate or cellular phenotype. Several other observations 
suggest that the AnxA6-2 isoform has several different roles compared to AnxA6-1 in 
relation to Ca
2+
 homeostasis as well as membrane transport (247, 248). However, based on 
current knowledge, the AnxA6-2 isoform does not contribute to tumorigenic behaviour.  
In addition, AnxA6 is multifunctional protein that negatively influences the activity of the 
EGFR/Ras/MAPK pathway. It binds to several negative regulators of the cascade such as 
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p120GAP and PKCα (66), and increases their ability to inhibit EGFR/Ras signaling. In fact, 
the elevated levels of AnxA6 decreased EGFR/Ras/MAPK activity and reduced oncogenic 
cell growth in several EGFR-related cell models (29). Thus, we hypothesized that high/low 
AnxA6 levels could be a potential biomarker that may predict the treatment outcome in 
EGFR-related cancers treated with drugs targeting the EGFR/Ras/MAPK pathway. 
Therefore, we compared cell and colony growth of cells lacking AnxA6 (A431wt) with cells 
overexpressing AnxA6 (A431-A6) in the presence of anti-cancer drugs targeting the 
EGFR/Ras/MAPK pathway. 
In this study, clonogenic and MTS assays demonstrated that AnxA6 overexpression increased 
the sensitivity towards the TKIs erlotinib, gefitinib, and AG1478 to decrease the oncogenic 
cell growth in A431 cells (Figure 6-12). Importantly, we observed an increased potency of 
erlotinib and gefitinib at low concentrations in A431-A6 cells compared to A431wt cells 
(Figure 6, 7, 9, 10).  Although 1µM erlotinib or gefitinib are generally considered too low for 
complete inhibition in cell culture studies (234, 237), it was able to induce substantial growth 
inhibition upon AnxA6 overexpression in A431 cells.  
Despite these findings, marginal difference was observed between the control and cetuximab-
treated cells, which did not fit expectations. Although we identified a trend of A431-A6 cells 
being more sensitive to cetuximab treatment than A431wt cells (Figure 13), we do not 
consider this significant, as our clonogenic assays showed no growth inhibition when we 
compared the suppression of growth following cetuximab monotherapy to the corresponding 
cell line control (Figure 13, 20, 21). Given that the literature confirms that cetuximab 
monotherapy markedly inhibits proliferation in A431 and other cell lines (233, 234), one 
could speculate that A431 cells used in this study may have developed resistance towards 
cetuximab. Consequently, interpretation of the data obtained from combining cetuximab with 
TKIs (Figure 20 and 21) is not forthcoming. 
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We have also explored the effect of AnxA6 on cell proliferation when MEK1/2 signaling was 
blocked. PD98059, a MEK1/2 inhibitor, was tested in clonogenic assays in A431 cells with 
and without AnxA6 overexpression. In agreement with the TKIs results, the proliferation and 
colony formation were more inhibited in A431-A6 cells than A431wt cells (Figure 15).  
4.3 Combinatorial drug treatment is potentiated upon AnxA6 
overexpression 
After our findings with monotherapies, we next investigated several combinatorial treatments 
in AnxA6 overexpressing cells. We first identified the influence of blocking MEK1/2 
signaling on the erlotinib-induced growth inhibition with elevated AnxA6 levels. The 
clonogenic assays revealed that the cotreatment of erlotinib with PD98059 was more 
effective in reducing oncogenic cell growth compared to single drug treatments (Figure 16 
and 17). Moreover, the combinatorial therapy resulted in a more potent suppression of colony 
formation in A431-A6 cells compared to A431wt cells. Similar results were obtained when 
gefitinib was combined with PD98059 under the same experimental conditions (Figure 18 
and 19). These data, in line with other studies, suggests that combining TKIs with MEK1/2 
inhibitors could be a successful strategy in reducing oncogenic cell growth (229-231), 
particularly in cancer cells with elevated AnxA6 levels. 
Given that AnxA6 inhibits EGFR in a PKCα-dependent manner, we followed these findings 
by another set of clonogenic assays in which we tested TKIs and PKCα inhibitors alone or in 
combination. Gö 6976, a PKCα and PKCβ1 inhibitor, moderately decreased colony formation 
of A431wt and A431-A6 cells; while BIM-I, a conventional PKC inhibitor, did not affect cell 
growth of any of the cell lines (Figure 22-25, 27-30). However, the cotreatment of erlotinib 
with either Gö 6976 or BIM-I effectively suppressed proliferation more than the individual 
drugs, and the growth inhibition was more pronounced in A431-A6 cells than A431wt cells. 
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Similar findings were observed with gefitinib combined with either PKCα-targeting drugs, 
except that the combination of gefitinib with Gö 6976 potently inhibited growth in both cell 
lines equally (97.7%). The increased potency of TKIs together with PKCα inhibitors in 
A431-A6 cells was unexpected, as PKCα knockdown restored EGFR signaling in A431-A6 
cells (29). These findings need further investigation, but we believe that other PKCα 
activities, not related to EGFR signaling, may have contributed to these observations. 
The increased potency of TKIs when administered alone or in combination with MEK1/2 or 
PKCα inhibitors could be owed to the tumor suppressor potential of AnxA6, which exerts its 
inhibitory effect on the EGFR/Ras/MAPK cascade in a p120GAP- and PKCα-dependent 
manner (22, 29). In 2009, Grewal and coworkers reported that elevated AnxA6 levels 
correlated with Ras inactivation in breast cancer cells (22). This inactivation was shown to be 
a consequence of AnxA6 binding to p120GAP which potentiated the targeting of p120GAP 
to Ras-GTP at the plasma membrane that lead to Ras downregulation (22). In addition, 
AnxA6 is a scaffolding protein for PKCα which potentiates PKCα membrane targeting and 
association with the EGFR, leading to EGFR signal termination (29). The interaction between 
AnxA6 and PKCα promotes EGFR downregulation via the increased ability of PKCα to 
phosphorylate EGFR at its threonine 654 leading to EGFR tyrosine phosphorylation 
inhibition (29). Both of these mechanisms would reduce the active pool of EGFR, Ras, and 
MAPK proteins, hence providing the basis for increased drug efficiency, even at low 
concentrations. 
In contrast, other studies have identified opposing findings regarding the role of AnxA6 in 
tumor progression. AnxA6 depletion in invasive BT-549 breast cancer cells induced rapid 
degradation of activated EGFR, and elevated the sensitivity towards EGFR-targeted TKIs. 
However, the reduced AnxA6 expression in these cells enhanced tumor proliferation (249). It 
should be noted that in contrast to the EGFR cancer models showed here and previously by 
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the Grewal group (22), BT-549 cells express only moderate levels of AnxA6 and EGFR. In 
BT-549 cells, the author discussed the role that AnxA6 plays in lipid rafts formation and 
consequently, maintaining a sustained localization of EGFR on the cell surface (250, 251). 
The modulation of lipid rafts formation upon AnxA6 depletion was suggested to disrupt the 
localization of EGFR on the membranes, inducing receptor degradation which promoted the 
sensitivity towards TKIs targeting the receptor in invasive breast cancer cells (249). Taken 
together, AnxA6 might exert different effects on EGFR, depending on the cell and cancer 
subtypes. 
Interestingly, our observations with Gö 6976 and BIM-I reflect the controversial results in 
various studies regarding the use of PKC inhibitors in cancer (29, 151, 232, 252-256). Gö 
6976 was investigated in another study, in which the response of cells depended on the cell 
lines tested (253). A431wt showed no growth inhibition, while H-Ras mutant NSCLC cell 
lines displayed a minimal growth inhibitory response (253). However, in the same study 
EGFR mutant cell lines showed major growth retardation, upon Gö 6976 treatment, both in 
vivo and in vitro (253). This significant inhibitory effect of Gö 6976 was suggested to be 
PKC-independent (253), particularly as the drug previously showed effects against other 
kinases (255, 256). In addition, BIM-I was tested against the K-Ras mutant cell line A549 
and displayed a minimal response in MTS assays (253). However, BIM-I showed 1.2 fold 
inhibition of serum-induced proliferation in lacto-somatotroph GH3 cells, and when 
combined with gefitinib further suppression of growth was observed that was more than the 
additive effect (232). This was referred to the possible inhibition of multiple signaling 
molecules by the various PKC isoforms inhibited by BIM-I (151, 232, 257).  
Although PKCα was reported to transactivate EGFR and its downstream signaling (254), 
other studies illustrated the inhibitory role of PKCα on EGFR activity (29, 252). In SCC12 
squamous carcinoma cells, multiple proteins such as caveolin-1, ganglioside GM3, and 
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tetraspanin CD82 are believed to modulate the binding of PKCα to EGFR in order to 
suppress the EGFR signaling (252). In addition, PKCα knockdown was found to minimally 
increase the cell growth of A431wt cells, and markedly elevate the number of colonies of 
AnxA6 overexpressing A431 cells, which pointed at the role that PKCα and its scaffolding 
proteins, including AnxA6, plays in EGFR inactivation (29). Therefore, given the multiple 
PKCα substrates involved in the EGFR pathway and other signaling cascades, the results for 
the combinatorial use of TKIs with PKCα inhibitors are difficult to interpret and require 
future investigations. 
4.4 Potential contribution of cPLA2 in EGFR signaling in 
annexin A6 overexpressing cells 
AnxA6 was also reported to induce inhibition of cPLA2 (75), an enzyme that was found 
elevated in various cancers (163, 258, 259). Hence, we employed the MTS assay to identify 
the impact of AnxA6 overexpression on the response of A431 cells to cPLA2 inhibition. In 
line with our previous findings, we found more suppression of growth in A431-A6 cells 
compared to A431wt cells, which would suggest an increased involvement of cPLA2 in the 
proliferation of A431-A6 cells. In fact, the negative influence of AnxA6 on cPLA2 activity 
was identified to be indirect and does not involve a direct interaction between AnxA6 and 
cPLA2 (75). cPLA2 is phosphorylated by ERK1/2 at serine 505, a process that increases the 
enzymatic activity of cPLA2. Thus, the inhibitory effect of AnxA6 on the EGFR/Ras/MAPK 
pathway could suppress cPLA2 activity (19, 260, 261). In addition, AnxA6 sequesters 
cholesterol in LE leading to the reduction of cholesterol levels in the Golgi apparatus. This 
change of cholesterol homeostasis interferes with cPLA2 translocation to the Golgi, a process 
that is required for the export of caveolin from Golgi to plasma membranes. Therefore, 
caveolae formation was inhibited, which would affect cellular signaling, lipid trafficking, 
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endocytosis, and the formation of membrane structures (3, 19, 66, 75, 76), all of which are 
relevant for EGFR activity. 
4.5 Conclusion and future directions 
Taken together, our data strongly support the hypothesis that elevated AnxA6 levels increase 
the efficacy of single or combinatorial treatments targeting EGFR-related cancer cell growth. 
This study supports current findings that combining different drugs targeting different 
members of the EGFR/Ras/MAPK signaling cascade may provide advanced therapeutic 
benefit. In summary, addressing Aims 1-4 delivered the following findings: 
 
 Aim 1: As hypothesized, AnxA6 expression increased the efficacy of EGFR-TKIs 
(erlotinib, gefitinib, AG1478) in EGFR overexpressing A431 cancer cells. 
 Aim 2: As hypothesized, AnxA6 expression increased the sensitivity of A431 cells 
towards monoclonal anti-EGFR antibodies (cetuximab).  
 Aim 3: The efficacy of EGFR-TKIs (erlotinib, gefitinib) was not improved when 
examined in combination with anti-EGFR antibodies in EGFR overexpressing cancer 
cells. This is irrespective of the presence or absence of AnxA6. 
 Aim 4: The efficacy of EGFR-TKIs (erlotinib, gefitinib) in combination with MEK1/2 or 
PKC inhibitors was increased upon AnxA6 expression in EGFR overexpressing A431 
cells. 
In particular, the treatment of A431 cells with TKIs combined with clinically proven 
MEK1/2 inhibitors could turn into a successful strategy, particularly in cancer cells with 
elevated AnxA6 levels. As such, this study places the determination of AnxA6 levels in the 
avenue of potential novel markers for predicting treatment responses in EGFR-related 
cancers.  
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Hence, in order to further develop AnxA6 levels as a prognostic tool in EGFR-related 
cancers, future studies should aim to: 
1. Correlate AnxA6 levels in EGFR-related tumors of patients with treatment outcomes.  
Up to date, Grewal and coworkers identified reduced AnxA6 levels in EGFR-related 
breast cancers as well as glioma (22, 29). Hence, in these cancers, AnxA6 expression 
could become a biomarker for predicting patient response to EGFR targeting anticancer 
agents. In addition, AnxA6 is often downregulated in melanoma, myeloma, gastric and 
liver cancers (262, 263). In particular in the latter, EGFR signaling contributes to 
hepatocarcinogenesis (264). All of these cancer types might become suitable for AnxA6 
to serve as a biomarker in the future.  
2. Determining the tumor growth of EGFR overexpressing cancer cells, such as A431 with 
and without AnxA6 using xenografts in mice, will be an important step to establish a 
tumor suppressor role of AnxA6 in vivo. Moreover, the treatment of A431wt and A431-
A6 xenografts with EGFR-TKIs or mAbs targeting EGFR will validate if increased drug 
sensitivity of AnxA6 expressing cells in cell cultures also occurs in more complex in vivo 
settings. Alternatively, exposing the AnxA6-KO mice to physiological stress, using well-
established treatments with carcinogens, could identify increased tumour initiation, 
growth and progression in the absence of AnxA6.  
3. Strategies to upregulate AnxA6 will remain difficult, as AnxA6 is a constitutively 
expressed gene that is not induced by hormones, steroids or other factors. However, with 
the ongoing improvements in gene therapy technologies, one could envisage AnxA6 
upregulation, possible via viral-mediated gene transfer. Grewal and coworkers have 
already succeeded to deliver and overexpress AnxA6 in the liver of mice using 
adenoviral expression vectors (Grewal et al., unpublished data). Alternatively, the 
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development of AnxA6-like molecules (peptides) could be examined for their potential to 
improve the efficacy of anti-EGFR therapeutics.  
 
Altogether, determining AnxA6 levels in EGFR-related tumors could become a useful tool in 
the future in order to predict patients most likely to benefit from drugs targeting oncogenic 
EGFR/Ras/MAPK activity. 
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